Myst inhibitors

HK40137423APending Publication Date: 2026-09-11ISOSTERIX INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125234
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-06-04
Filing Date
2026-06-24
Publication Date
2026-09-11

Smart Images

  • Figure 00000515_0000
    Figure 00000515_0000
  • Figure 00000529_0000
    Figure 00000529_0000
  • Figure 00000594_0000
    Figure 00000594_0000
Patent Text Reader

Abstract

Provided herein are compounds and pharmaceutically acceptable derivatives thereof that are MYST inhibitors. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds to treat subjects suffering from hyperproliferative diseases, including cancer.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480062133.3 (22) Application Date 2024.09.26 (30) Priority Data 63 / 585,817 2023.09.27 US 63 / 558,419 2024.02.27 US 63 / 655,961 2024.06.04 US (85) PCT International Application Entering National Phase Date 2026.03.26 (86) PCT International Application Application Data PCT / US2024 / 048535 2024.09.26 (87) PCT International Application Publication Data WO2025 / 072423 EN 2025.04.03 (71) Applicant: Esosterix, Inc. Address: California, USA (72) Inventor: Rupa Rae, A. Pandey, L.J. Holsinger (74) Patent Agency: King & Wood Mallesons, Beijing 11256 Patent Attorney: Tai Hong (51) Int.Cl. C07D 413 / 06 (2006.01) C07D 413 / 12 (2006.01) C07D 413 / 14 (2006.01) C07D 417 / 12 (2006.01) C07D 417 / 14 (2006.01) C07D 498 / 04 (2006.01) C07D 515 / 08 (2006.01) C07D 519 / 00 (2006.01) A61P 35 / 00(2006.01) A61K 31 / 423(2006.01) A61K 31 / 424(2006.01) A61K 31 / 4439(2006.01) C07D 487 / 04(2006.01) (54) Invention Title: MYST Inhibitor (57) Abstract: This document provides compounds as MYST inhibitors and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing said compounds and methods of using said compounds to treat subjects suffering from hyperproliferative diseases, including cancer. Claims: 20 pages Description: 253 pages Serial Listing (Electronic Publication) CN 122003411 A 2026.05.08 CN 1 22 00 34 11 A 1. A compound of formula I: or a pharmaceutically acceptable derivative thereof,Wherein: a is 0 to 2; R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2 and Z3 Choose from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 choose from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 choose from (i). Or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–,Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; Claims 1 / 20 page 2 CN 122003411 A R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2- R19, ​​-O-(CH2)2-R19 or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR20R21. 2. A compound of formula I: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is H, alkyl, haloalkyl, or halogen; and R2 is alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is an alkyl group or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, and one of Z2 and Z3 is C.And the other of Z2 and Z3 is N, (ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; Z5 is CR5; Claims 2 / 20 page 3 CN 122003411 A Z6 is N or CH; R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x or CH2, wherein x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 Together with the atoms they are attached to, R7 forms a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19, or -NR20R21; among which R19 R1 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10. 3. A compound of formula I: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is H, alkyl, haloalkyl, or halogen; and R2 is alkyl, cycloalkyl, or haloalkyl,Or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; Claims 3 / 20 pages 4 CN 122003411 A R4 is H Or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is N. The symbol is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O or S(O)x, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–,Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10. 4. A compound of formula I: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; R2 and R4 together form a heteroalkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 It is an alkyl group or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N, (ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH,One of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl; or (ii) R5 and R16 together form an alkylene or heteroalkylene group; X The atom is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 is H, an alkyl group, or a haloalkyl group, or (ii) Het is a 5- or 6-membered heteroaryl group, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is –C(O)R17, –S(O)R18, or –SO2R18; R17 The alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2- R19, -O-(CH2)2- R19 or -NR20R21; wherein R19 is -OR9 or -NR9R10.Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10. Claims 5 / 20, page 6, CN 122003411 A 5. A compound of formula I: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is H, alkyl, haloalkyl, or halogen; R2 is alkyl, cycloalkyl, or haloalkyl; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 R5 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl.Or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is CR22R23, wherein R22 and R23 are each independently H or alkyl; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2-, and R6 and Het together with the atoms of claim 6 / 20, page 7, CN 122003411 A to which they are connected form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7-bicyclic ring system; R7 is -C(O)R17; and R17 is alkoxy, alkenyloxy, alkynyloxy, or -O-(CH2)2-R19 6. The compound according to any one of claims 1 to 5, having formula Ia: or a pharmaceutically acceptable derivative thereof. 7. The compound according to any one of claims 1 to 6, wherein: R1 is H; R2 is alkyl, cycloalkyl, or haloalkyl; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; X is CH2; and R17 is alkoxy. 8. The compound according to any one of claims 1 to 7, wherein: R1 is H; R2 is alkyl or haloalkyl; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; X is CH2; and R17 is alkoxy. 9. A compound of formula II: or a pharmaceutically acceptable derivative thereof,Wherein: a is 0 to 2; R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; claims 7 / 20 page 8 CN 122003411 A b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is N. R5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–,Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR20R21. 10. A compound of formula II: (Claims 8 / 20, page 9, CN 122003411 A) or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii); (i) R1 is alkyl, cycloalkyl, or haloalkyl; and R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 Each is independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, and one of Z2 and Z3 is C,And the other of Z2 and Z3 is N, (ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; Z5 is CR5; Z6 is N or CH; R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het Together with the atoms they are attached to, they form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, methylaminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2- R19, -O-(CH2)2- R 19 or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10. 11. A compound of formula II: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl, cycloalkyl or haloalkyl, and R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy or halogen,Or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2 and Z3 are selected from (i) and (ii). Or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5 and Z6 are selected from (i), (ii), (iii) or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; Claims 10 / 20 pages 11 CN 122003411 A R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O or S(O)x, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–,Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10. 12. A compound of formula II: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is alkyl, cycloalkyl, or haloalkyl; R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 Each is independently H, OH, alkoxy, or alkyl, or forms a heterocyclic group together with the nitrogen atom to which it is attached; Claims 11 / 20 pages 12 CN 122003411 A R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C;Or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5 and Z6 are selected from (i), (ii), (iii) or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH, (ii) Z4 is CR16, Z5 is N, and Z6 is CH, (iii) Z4 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 Together they form an alkylene or heteroalkylene; X is CR22R23, wherein R22 and R23 are each independently H or alkyl; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2-, and R6 and Het together with the atoms to which they are attached form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7-bicyclic ring system; R7 is -C(O)R17; and R17 is alkoxy, alkenyloxy, alkynyloxy, or -O-(CH2)2-R19; wherein R19 is -OR9 or -NR9R10. 13. The compound according to any one of claims 9 to 12, wherein the compound has formula IIa: or a pharmaceutically acceptable derivative thereof. 14. The compound according to any one of claims 9 to 13, wherein: R1 is an alkyl, cycloalkyl, or haloalkyl; R2 is H; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is an alkyl or alkoxy; R11 is an alkyl or alkoxy; X is CH2; and R17 is an alkoxy. 15. The compound according to any one of claims 9 to 13,Wherein: R1 is an alkyl or haloalkyl; R2 is H; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; X is CH2; and R17 is alkoxy. 16. A compound of formula III: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is N. R5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl.Or, as stated on page 13 / 20 of the claims, CN 122003411 A (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, wherein x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, an alkyl, or a haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms to which they are attached form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is –C(O)R17, –S(O)R18, or –SO2R18; R17 The following are alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 It is an alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR20R21. 17. A compound of formula III: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently an alkyl, cycloalkyl, or haloalkyl,Or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Claims 14 / 20 pages 15 CN 122003411 A Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; Z5 is CR5; Z6 is N or CH; R5 and R16 together form an alkylene or heteroalkylene group; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 (ii) Het is a 5- or 6-membered heteroaryl group, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10. 18. A compound of formula III: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or AC(=N-O-R9)(R12) as claimed on page 15 / 20 of CN 122003411; R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2 and Z3 are selected from (i), (ii) or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N.(ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH, (ii) Z4 is CR16, Z5 is N, and Z6 is CH, (iii) Z4 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O or S(O)x, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 The alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2- R19, -O-(CH2)2- R19 or -NR20R21; wherein R19 is -OR9 or -NR9R10.Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10. 19. The compound according to any one of claims 16 to 18, wherein the compound has formula IIIa: Claims 16 / 20 pages 17 CN 122003411 A. 20. A compound of formula IIIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 R14 is an alkyl group or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16, wherein R16 is H, alkyl, haloalkyl, alkoxy, halogen, alkenyl, or alkynyl; R5 is H, alkyl, haloalkyl, alkoxy, halogen, alkenyl, or alkynyl; X is O, S(O)x Or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 is H, an alkyl group, or a haloalkyl group, or (ii) Het is a 5- or 6-membered heteroaryl group.R6 is –(CH2)1-2–, and R6 and Het together with the atoms of claim 17 / 20, CN 122003411 A to which they are connected form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring system; R7 is –C(O)R17 or –SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2- R19, ​​-O-(CH2)2-R19 or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10. 21. The compound according to any one of claims 16 to 20, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each alkyl, or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl. 22. The compound according to any one of claims 1 to 4, 6, 9 to 11, 13 and 16 to 21, wherein X is O. 23. The compound according to any one of claims 1, 2, 4 to 10 and 11 to 21, wherein X is CH2. 24. The compound according to any one of claims 1 to 23,Wherein a is 0 or 1. 25. The compound according to any one of claims 1 to 8, wherein R2 is an alkyl group. 26. The compound according to any one of claims 1 to 8, wherein R2 is a haloalkyl group. 27. The compound according to any one of claims 1 to 8, wherein R2 is a difluoromethyl group. 28. The compound according to any one of claims 9 to 15, wherein R1 is an alkyl group. 29. The compound according to any one of claims 9 to 15, wherein R1 is a haloalkyl group. 30. The compound according to any one of claims 9 to 15, wherein R1 is a difluoromethyl group. 31. The compound according to any one of claims 1 to 6, wherein R1 is H. 32. The compound according to any one of claims 9 to 15, wherein R2 is H. 33. The compound according to any one of claims 16 to 21, wherein R1 and R2 together form a C1-4 alkylene group optionally substituted with one or more halogens or methyl groups. 34. The compound according to any one of claims 1 to 33, wherein b is 1 or 2. Claims 18 / 20, Page 19, CN 122003411 A 35. The compound according to any one of claims 1 to 6, 9 to 13, and 16 to 21, wherein R8 is H, phenyl, 4-fluorophenyl, morpholinyl, COOH, COOMe, C(=NH)NHOH, tetrazolyl, oxadiazolyl, triazolyl, pyridyl, imidazolyl, oxazolidinyl, NHC(O)OMe, cyano, hydroxyl, amino, or acetamido. 36. The compound according to any one of claims 1 to 35, wherein R8 is hydrogen. 37. The compound according to any one of claims 1 to 36, wherein R4 is H. 38. The compound according to any one of claims 1 to 37, wherein R4 is methoxy. 39. The compound according to any one of claims 1 to 38, wherein Z1 is NH or O, and Z2 and Z3 are C. 40. The compound according to any one of claims 1 to 39, wherein Z1 is O, and Z2 and Z3 are C. 41. The compound according to any one of claims 1 to 40, wherein Z4 is N. 42. The compound according to any one of claims 1 to 40, wherein Z4 is CR16. 43. The compound according to any one of claims 1 to 42, wherein R5 is H, cyano, alkoxy, or alkyl.And R16 is H, alkyl, alkoxy, halogen, or alkynyl. 44. The compound according to any one of claims 1 to 43, wherein R5 is H, cyano, methoxy, or methyl, and R16 is H, methyl, ethyl, isopropyl, tert-butyl, methoxy, chlorine, fluorine, ethynyl, or propynyl. 45. The compound according to any one of claims 1 to 44, wherein Het is a 5- or 6-membered heteroaryl, and R6 is H or alkyl. 46. The compound according to any one of claims 1 to 45, wherein Het is a 5-membered heteroaryl, and R6 is H or methyl. 47. The compound according to any one of claims 1 to 46, wherein Het is pyrazolyl, oxazolyl, thiazolyl, or pyridinyl, and R6 is H or methyl. 48. The compound according to any one of claims 1 to 47, wherein Het is pyrazolyl, and R6 is H or methyl. 49. The compound according to any one of claims 1 to 48, wherein R7 is -C(O)R17. 50. The compound according to any one of claims 1 to 48, wherein R7 is -S(O)R18. 51. The compound according to any one of claims 1 to 48, wherein R7 is -SO2R18. 52. The compound according to any one of claims 1 to 6, 9 to 13, and 16 to 21, wherein R17 is alkyl, alkoxy, alkenyl, haloalkenyl, alkynyl, NR20R21, or hydroxyalkynyl. 53. The compound according to any one of claims 1 to 6, 9 to 13, and 16 to 21, wherein R17 is methyl, methoxy, NHMe, vinyl, 1-fluoro-1-vinyl, ethynyl, or 1-propynyl-1-yl. 54. The compound according to any one of claims 1 to 53, wherein R18 is methyl or tert-butyl. 55. The compound of any one of claims 1 to 54, wherein the compound is any one of the compounds disclosed herein. 56. A pharmaceutical composition comprising: the compound of any one of claims 1 to 55; and a pharmaceutically acceptable carrier. 57. A method of treating a subject suffering from cancer, the method comprising administering to the subject the compound of any one of claims 1 to 55 or the pharmaceutical composition of claim 56. 58. A method of treating a subject suffering from myc-driven cancer.The method includes administering to the subject the compound of any one of claims 1 to 55 or the pharmaceutical composition of claim 56, as per claim 19 / 20, page 20, CN 122003411 A. Claims 20 / 20, page 21, CN 122003411 A. Related applications for MYST inhibitors

[0001] This application claims the priority of U.S. Provisional Patent Application No. 63 / 585,817, filed September 27, 2023; U.S. Provisional Patent Application No. 63 / 558,419, filed February 27, 2024; and U.S. Provisional Patent Application No. 63 / 655,961, filed June 4, 2024, the disclosures of which are incorporated herein by reference in their entirety.

[0002] Sequence Listing This application contains a sequence listing, which is submitted as an XML file named "ISTX104WO_SL.xml" of size 5406 bytes, created on September 11, 2024, and is incorporated herein by reference in its entirety. Technical Field

[0003] This document provides compounds and compositions for inhibiting lysine acetyltransferases (KAT) of the MYST family. In one embodiment, a method of treating diseases including hyperproliferative disorders is provided using the compounds and compositions provided herein. In another embodiment, the hyperproliferative disorder is cancer. Background Art

[0004] The MYST family of enzymes is KAT, and includes KAT6A (also known as MOZ or MYST3), KAT6B (also known as MORF or MYST4), KAT5 (also known as Tip60), KAT7 (also known as HBO1 or MYST2) and KAT8 (also known as MOF or MYST1) (see, for example, Wiesel-Motiuk et al., Drug Resistance Updates 2020, 53, 100729; Wapenaar et al., Clinical Epigenetics 2016, 8(59), 1 (DOI 10.1186 / s13148-016-0225-2)). The MYST family of KAT is particularly important in regulating the cell cycle (Carrozza et al., Trends in Genetics 2003, 19, 321-329).

[0005] Dysregulation of KAT6 protein expression supports tumor progression (see, for example,Trisciuoglio et al., Stem Cells Int. 2018, Article ID 8908751 (https: / / doi.org / 10.1155 / 2018 / 8908751)). Dysregulation of gene amplification, overexpression, or mutation via KAT6A has been documented in various cancer types, including breast cancer, lung adenocarcinoma, ovarian cancer, colorectal adenocarcinoma, and cervical cancer (see, for example, Huang et al., Molecular and Cellular Biology 2016, 63, 1900–1907; Zack et al., Nature Genetics 2013, 45, 1134–1140). The locus containing the gene targeting KAT6A (8p11–p12 amplicons) has been reported to be the 12th most frequently amplified region of the genome across all cancer types (see, for example, Zack et al., 2013, ibid.). In acute myeloid leukemia (AML), recurrent oncogenic fusions of KAT6A have been documented to drive transformation into a malignant state (see, for example, Sheikh et al., Blood 2015, 125, 1910–1921). Translocations of KAT6A and fusions with mates such as CBP, p300, TIF2, and NCOA3 are known to result in aggressive forms of AML (see, for example, Sheikh et al., 2015, ibid.).

[0006] In addition to its role in epigenetic regulation, KAT also acetylates nonhistone proteins. By modifying the acetylation state of nonhistone proteins, KAT is involved in regulating protein function and stability, protein-protein and protein-DNA interactions, and regulating enzyme activity (see, for example, Glozak et al., Gene 2005, 363, 15–23; Das et al., IUBMB Life 2005, 57, 137–148). Specification 1 / 253 pages 22 CN 122003411 A

[0007] Therefore, there is a need for MYST inhibitors for the treatment of hyperproliferative diseases, including cancer. Summary of the Invention

[0008] This document provides a compound of formula I: or a pharmaceutically acceptable derivative thereof, wherein R1-R4, R6, R7, a, Het, X and Z1-Z6 are as defined elsewhere herein.

[0009] This document also provides a compound of formula II: or a pharmaceutically acceptable derivative thereof,Wherein R1-R4, R6, R7, a, Het, X, and Z1-Z6 are as defined elsewhere herein.

[0010] This document also provides a compound of formula III: or a pharmaceutically acceptable derivative thereof, wherein R1-R4, R6, R7, a, Het, X, and Z1-Z6 are as defined elsewhere herein.

[0011] Pharmaceutical compositions comprising a compound of formula I, II, or III and a pharmaceutically acceptable excipient are also provided.

[0012] In one embodiment, the compound of formula I, II, or III provided herein inhibits one or more of the MYST family of lysine acetyltransferases. In another embodiment, the compound provided herein inhibits KAT6A. In another embodiment, the compound provided herein is a covalent inhibitor of KAT6A. Without being bound by any theory, in one embodiment, the compound provided herein inhibits KAT6A by covalent modification of a cysteine ​​residue at or near the Ac-CoA binding site. In another embodiment, the compound provided herein is a non-covalent inhibitor of KAT6A. Instructions 2 / 253 pages 23 CN 122003411 A

[0013] In other embodiments, methods for treating hyperproliferative diseases by applying compounds or compositions provided herein are provided. In one embodiment, the hyperproliferative disease is cancer. In another embodiment, the cancer is breast cancer, lung cancer, ovarian cancer, colon cancer, prostate cancer, uterine / cervical cancer, or leukemia. In another embodiment of the methods provided herein, the Formula I compound is used as a single agent or in combination with standard care treatment for a particular cancer.

[0014] In another embodiment, a method for inhibiting MYST enzymes by contacting MYST enzymes or compositions containing MYST enzymes with compounds or compositions provided herein is provided. In another embodiment, a method for inhibiting KAT6A by contacting KAT6A or compositions containing KAT6A with compounds or compositions provided herein is provided. Detailed Description

[0015] I. Definitions Several terms are defined below for ease of understanding of the disclosure described herein.

[0016] Unless otherwise specified, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications are incorporated herein by reference in their entirety. Where a term has multiple definitions herein, those definitions in this section shall prevail unless otherwise stated.

[0017] Unless otherwise expressly stated, the singular forms “an,” “a,” and “the / said” include a plural referent.

[0018] As used herein, “subject” is an animal, such as a mammal, including humans,Such as patients.

[0019] As used herein, bioactivity refers to the in vivo activity or physiological response of a compound after administration in vivo of a compound, composition, or other mixture. Therefore, bioactivity includes the therapeutic effects and pharmacokinetic behavior of such compounds, compositions, and mixtures. Such activity can be observed in in vitro systems designed to test bioactivity.

[0020] As used herein, pharmaceutically acceptable derivatives of a compound include, but are not limited to, its salts, esters, enol ethers, enol esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, inclusion complexes, solvates, or hydrates. Such derivatives can be readily prepared by those skilled in the art using methods known for such derivatization. The resulting compounds can be administered to animals or humans without significant toxicity and are pharmaceutically active or prodrugs. Pharmaceutically acceptable salts include, but are not limited to, amine salts, such as, but not limited to, N,N'-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucosamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-methylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as, but not limited to, lithium, potassium and sodium; alkaline earth metal salts, such as, but not limited to, barium, calcium and magnesium; transition metal salts, such as, but not limited to, zinc; and inorganic salts, such as, but not limited to, sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, mineral acid salts, such as, but not limited to, hydrochlorides and sulfates; and organic acid salts, such as, but not limited to, acetates, lactates, malates, tartrates, citrates, ascorbic acid salts, succinates, butyrates, valerates, methanesulfonates and fumarates. Pharmaceutically acceptable esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl esters with acidic groups, including but not limited to carboxylic acids, phosphoric acids, phosphonic acids, sulfonic acids, sulfinic acids, and boric acids. Pharmaceutically acceptable enol ethers include, but are not limited to, derivatives of the formula C=C(OR), where R is alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl. Pharmaceutically acceptable enol esters include, but are not limited to, derivatives of the formula C=C(OC(O)R), where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl. Pharmaceutically acceptable solvates and hydrates are complexes of compounds with one or more solvents or water molecules, or 1 to about 100 solvents or water molecules, or 1 to about 10 solvents or water molecules, or 1 to about 2, 3, or 4 solvents or water molecules.

[0021] As used herein, treatment means any manner in which one or more symptoms of a disease or condition are improved or otherwise beneficially altered. Treatment also includes any pharmaceutical use of the compositions described herein.Such as for use in treating hyperproliferative disorders.

[0022] As used herein, improving symptoms of a particular condition by administering a particular compound or pharmaceutical composition means any relief that can be attributed to or associated with the administration of the compound or pharmaceutical composition, whether permanent or temporary, lasting or transient.

[0023] As used herein, and unless otherwise stated, the terms “manage,” “managing,” and “management” include preventing the recurrence of a particular disease or condition in a subject who already has the disease or condition, and / or prolonging the time a subject with the disease or condition maintains remission. These terms include modulating the threshold, development, and / or duration of the disease or condition, or altering how a subject responds to the disease or condition.

[0024] When parts are designated by their conventional chemical formula (written from left to right), they also contain chemically identical parts (which will be produced by a structure written from right to left), for example, -CH2O- is equivalent to -OCH2-.

[0025] Unless otherwise stated, the term "alkyl" itself or as part of another substituent means a straight-chain (i.e., unbranched) or branched saturated hydrocarbon group, which may include divalent and polyvalent groups having a specified number of carbon atoms (i.e., C1-C10 means one to ten carbons). Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, their homologues and isomers such as n-pentyl, n-hexyl, n-heptyl, n-octyl, etc.

[0026] Unless otherwise stated, the term "alkenyl" itself or as part of another substituent means a straight-chain (i.e., unbranched) or branched hydrocarbon group having one or more carbon-carbon double bonds, which may include divalent and polyvalent groups having a specified number of carbon atoms (i.e., C1-C10 means one to ten carbons). Examples of alkenyl groups include, but are not limited to, vinyl (i.e., ethenyl), 2-propenyl, crotonyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), and higher homologues and isomers.

[0027] Unless otherwise stated, the term "alkynyl" itself or as part of another substituent means a straight-chain (i.e., unbranched) or branched chain hydrocarbon group having one or more carbon-carbon triple bonds, which may include divalent and polyvalent groups having a specified number of carbon atoms (i.e., C1-C10 means one to ten carbons). Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl and 3-propynyl, 3-butynyl, and higher homologues and isomers.

[0028] The term "alkylene" itself or as part of another substituent means a divalent group derived from an alkyl group, such as, but not limited to, -CH2CH2CH2CH2-. generally,Alkyl (or alkylene) groups will have 1 to 24 carbon atoms, including those with 10 or fewer carbon atoms. “Lower alkyl” or “lower alkylene” refers to short-chain alkyl or alkylene groups that typically have six or fewer carbon atoms.

[0029] The terms “alkoxy,” “alkylamino,” and “alkylthio” (or thioalkoxy) are used in their conventional sense and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.

[0030] Unless otherwise stated, the term “heteroalkyl”, used alone or in combination with another term, means a straight-chain or branched hydrocarbon group consisting of heteroatoms selected from the group consisting of O, N, P, Si, and S, wherein nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen atom may have alkyl substituents to satisfy a valence and / or may optionally be quaternized. Heteroatoms O, N, P, Si, and S may be placed at any internal position within the heteroalkyl group. Examples include, but are not limited to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. At most two heteroatoms can be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. Similarly, the term "heteroalkylene" itself, or as part of another substituent, refers to a divalent group derived from a heteroalkylene group, such as, but not limited to, -CH2-CH2-S-CH2-CH2- and –CH2-S-CH2-CH2-NH-CH2-. For alkylene and heteroalkylene linking groups, the orientation of the linking group is not implied by the direction in which the formula of the linking group is written. For example, the formula –C(O)2R'- represents both –C(O)2R'- and –R'C(O)2-.

[0031] Unless otherwise stated, the terms “cycloalkyl” and “heterocycloalkyl”, used alone or in combination with other terms, refer to the cyclic form of “alkyl” and “heteroalkyl”, including bicyclic, tricyclic, spirocyclic, and bridged bicyclic groups. Furthermore, for heterocycloalkyl,Heteroatoms can occupy positions where the heterocycle is attached to the rest of the molecule. Examples of cycloalkyl groups include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, norcamphenyl, bicyclo[2.2.2]octyl, etc. Examples of heterocycloalkyl groups include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophene-2-yl, tetrahydrothiophene-3-yl, 1-piperazinyl, 2-piperazinyl, 1- or 2-azabicyclo[2.2.2]octyl, etc.

[0032] Unless otherwise stated, the term "halogen" itself or as part of another substituent refers to a fluorine, chlorine, bromine, or iodine atom. Furthermore, terms such as "halogenated alkyl" mean including both monohalogenated and polyhalogenated alkyl groups. For example, the term "haloalkyl (C1-C4)" means, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, etc. Similarly, unless otherwise stated, the terms "cycloalkenyl," "cycloynyl," "heterocyclic alkenyl," and "heterocyclic alkenyl," used alone or in combination with other terms, refer to the cyclic forms of "alkenyl," "ynyl," "heteroalkenyl," and "heteroynyl," including bicyclic, tricyclic, spirocyclic, and bridged bicyclic groups, respectively.

[0033] Unless otherwise stated, the term "aryl" means a polyunsaturated aromatic hydrocarbon substituent, which may be a monocyclic or fused together or covalently linked polycyclic (one to three rings in one embodiment). The term "heteroaryl" refers to an aryl group containing one to four heteroatoms (selected from N, O, or S) in a ring, wherein the nitrogen and sulfur atoms are optionally oxidized, and one or more nitrogen atoms are optionally quaternized. The heteroaryl group may be attached to the rest of the molecule by a carbon or a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isooxazolyl, 4-isooxazolyl, 5-isooxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl. 2-Furanyl, 3-Furanyl, 2-Thienyl, 3-Thienyl, 2-Pyridyl, 3-Pyridyl, 4-Pyridyl, 2-Pyrimidinyl, 4-Pyrimidinyl, 5-Benzothiazolyl, Purinyl, 2-Benzimidazolyl, 5-Indoleyl, 1-Isoquinolinyl, 5-Isoquinolinyl, 2-Quinoxolinyl, 5-Quinoxolinyl, 3-Quinoxolinyl, and 6-Quinoxolinyl. The substituent moiety of aryl and heteroaryl ring systems may be selected from the group of acceptable substituent moiety described herein. The term "heteroarylonium" refers to a heteroaryl group with a positive charge on one or more heteroatoms.

[0034] As used herein,The term “oxo” refers to an oxygen atom to which a double bond is bonded to a carbon atom.

[0035] Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “aryl,” and “heteroaryl”) means both substituted and unsubstituted forms of the indicated group. Non-limiting examples of the substituent portion of each type of group are provided below.

[0036] In one embodiment, the substituent moiety of alkyl, heteroalkyl, alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups is selected from deuterium, -OR', =O, =NR', =N-OR', -NR'R'', -SR', halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO2R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)2R', -NR-C(NR'R''R''')=NR'''', -NR-C(NR'R'')= NR''', -S(O)R', -S(O)2R', -S(O)2NR'R'', -NRSO2R', -NRSO2NR'R'', -CN, and –NO2, ranging from zero to the number of hydrogen atoms in such groups. In one embodiment, the substituent portion of the cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups further includes substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, and substituted and unsubstituted alkynyl groups. In one embodiment, R', R'', R''', and R'''' are each independently hydrogen, substituted and unsubstituted heteroalkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocycloalkyl, substituted and unsubstituted aryl (e.g., aryl substituted with 1-3 halogen atoms), substituted and unsubstituted alkyl, alkoxy, or thioalkoxy groups, or aralkyl groups. For example, when the compounds provided herein contain more than one R group, each of the R groups is independently chosen as a separate R', R'', R''', and R'''' group (when more than one of these groups is present). When R' and R'' are attached to the same nitrogen atom, they can combine with the nitrogen atom to form a 4-membered, 5-membered, 6-membered, or 7-membered ring. For example, -NR'R'' means, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. Based on the above discussion regarding the substituent moiety, those skilled in the art will understand that the term "alkyl" means including groups comprising a carbon atom bonded to a group other than a hydrogen group, such as haloalkyl (e.g., -CF3 and –CH2CF3) and acyl (e.g.,-C(O)CH3, -C(O)CF3, -C(O)CH2OCH3, etc.).

[0037] In one embodiment, the substituent portion of the aryl and heteroaryl groups is selected from deuterium, halogens, substituted and unsubstituted alkyl groups, substituted and unsubstituted alkenyl groups, substituted and unsubstituted alkynyl groups, -OR', -NR'R'', -SR', -SiR'R''R''', -OC(O)R', -C(O)R', -CO2R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR''C(O)2R', -NR-C(NR'R''R''')=NR'''', -NR-C(NR'R'')=NR''', -S(O) R', -S(O)2R', -S(O)2NR'R'', -NRSO2R', -CN and -NO2, -R', -N3, -CH(Ph)2, fluoro(C1-C4)alkoxy and fluoro(C1-C4)alkyl, in a number range equal to the total number of hydrogens in the aromatic ring system; and wherein R', R'', R''' and R''''' in one embodiment are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. For example, when the compounds provided herein contain more than one R group, each group in the R group is independently selected as a separate R', R'', R''' and R'''' group (when more than one of these groups is present).

[0038] Two of the substituent portions on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -Q'-C(O)-(CRR')q-Q''-, wherein Q' and Q'' are independently –NR-, –O-, –CRR'-, or a single bond, and q is an integer from 0 to 3. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced by substituents of the formula -A-(CH2)r-B-, wherein A and B are independently –CRR'-, –O-, –NR-, –S-, –S(O)-, –S(O)2-, –S(O)2NR'-, or a single bond, and r is an integer from 1 to 4. One of the single bonds in the newly formed ring may optionally be replaced by a double bond. Alternatively, two substituents in the substituent moiety on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced by substituents of the formula –(CRR')s-X'-(CR''R''')d-, where s and d are independent integers from 0 to 3.And X' is –O-, –NR'-, –S-, –S(O)-, –S(O)2-, or –S(O)2NR'-. In one embodiment, the substituent moieties R, R', R'', and R''' are independently selected from hydrogen, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl groups, substituted and unsubstituted heterocycloalkyl groups, substituted and unsubstituted aryl groups, and substituted or unsubstituted heteroaryl groups.

[0039] As used herein, the term “heteroatom” or “cycloheteroatom” means including oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0040] As used herein, a prodrug is a compound that, when administered in vivo, is metabolized by one or more steps or processes or otherwise undergoes a chemical change under physiological conditions or is otherwise converted into a biologically, pharmaceutically, or therapeutically active form of the compound. Furthermore, a prodrug can be converted into a biologically, pharmaceutically, or therapeutically active form of the compound in an in vitro environment by chemical or biochemical methods. For example, when a prodrug is placed together with a suitable enzyme or chemical reagent in a transdermal patch reservoir, it can be converted into the compounds of the present invention.

[0041] Some of the compounds provided herein may exist in both solvated and hydrated forms, including the form described in the specification 6 / 253 page 27 CN 122003411 A. Generally, the solvated form is equivalent to the hydrated form and is included within the scope of this disclosure. Some of the compounds provided herein may exist in a variety of crystalline or amorphous forms. Generally, all physical forms are equivalent for the purposes considered herein and are intended to be covered within the scope of this disclosure.

[0042] Some of the compounds provided herein have asymmetric carbon atoms (optical centers) or double bonds; racemates, diastereomers, tautomers, geometric isomers, and monomeric isomers are covered within the scope of this disclosure. The compounds provided herein do not include those compounds known in the art that are too unstable to be synthesized and / or isolated.

[0043] The compounds provided herein may also contain atomic isotopes in non-natural proportions at one or more atoms constituting such compounds. For example, the compounds may be radiolabeled with radioactive isotopes such as, for example, tritium (3H), iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds provided herein, whether or not radioactive, are included within the scope of this disclosure.

[0044] II. Compounds for Compositions and Methods In one embodiment, a compound of formula I for use in the compositions and methods provided herein is provided: or a pharmaceutically acceptable derivative thereof,Wherein: a is 0 to 2; R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2 and Z3 are selected from (i), (ii) or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5 and Z6 are selected from (i), (ii), (iii) or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR20R21.

[0045] In one embodiment, a compound of formula Ia is provided for use in the compositions and methods provided herein: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, and one of Z2 and Z3 is C.And the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form alkylene or heteroalkylene; X is O, S(O)x or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring system; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR20R21.

[0046] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R8 is H, CN, OH, alkoxy, aryl, heteroaryl, NR9R10, or C(O)R11; R9 is H and R10 is H or C(O)R13; wherein R13 is alkyl or alkoxy; and R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl,Or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0047] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R8 is H, CN, OH, alkoxy, aryl, NR9R10 or C(O)R11; R9 is H and R10 is C(O)R13; wherein R13 is alkyl; and R11 is alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy or alkyl, and R16 is H, alkyl, alkoxy, halogen or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl.

[0048] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R1 and R2 together form a C2-4 alkylene group.

[0049] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R1 and R2 together form a propylidene group.

[0050] In another embodiment, the compound used in the compositions and methods provided herein has formula I: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is H, alkyl, haloalkyl, or halogen; and R2 is alkyl, cycloalkyl, or haloalkyl.Or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; Specification 10 / 253 Page 31 CN 122003411 A R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; Z5 is CR5; Z6 is N or CH; R5 and R16 together form an alkylene or heteroalkylene group; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 is H, an alkyl group, or a haloalkyl group; or (ii) Het is a 5- or 6-membered heteroaryl group. The heteroaryl group has R6 as –(CH2)1-2-, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is –C(O)R17, –S(O)R18, or –SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19. -O-(CH2)2-R19 or -NR20R21; where R19 is -OR9 or -NR9R10.Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10.

[0051] In another embodiment, the compound used in the compositions and methods provided herein has formula Ia: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is H, alkyl, haloalkyl or halogen; and R2 is alkyl, cycloalkyl or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; R5 and R16 together form an alkylene or heteroalkylene group; X It is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 is H, an alkyl group, or a haloalkyl group, or (ii) Het is a 5- or 6-membered heteroaryl group, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0052] In another embodiment, the compounds used in the compositions and methods provided herein have formula I or Ia, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is H; and R2 is alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 together form an alkylene group; X is O or CH2; R17 is an alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is an alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0053] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is H; and R2 is an alkyl or haloalkyl,Or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is an alkyl group; R11 is an alkoxy group; R5 and R16 together form an alkylene group; X is O or CH2; R17 is an alkyl group, haloalkyl group, alkoxy group, alkoxyalkyl group, aminoalkyl group, alkenyl group, haloalkenyl group, ynyl group, or hydroxymethylynyl group; and R18 is an alkyl group, haloalkyl group, alkoxyalkyl group, aminoalkyl group, alkenyl group, haloalkenyl group, ynyl group, or hydroxymethylynyl group.

[0054] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R5 and R16 together form a C3-5 alkylene group.

[0055] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R5 and R16 together form a propylene group.

[0056] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein X is 0 or S(O)x, where x is 0 to 2. In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein X is 0 or S.

[0057] In another embodiment, the compound used in the compositions and methods provided herein has Formula I: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is H, alkyl, haloalkyl or halogen; and R2 is alkyl, cycloalkyl or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N.(ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH, (ii) Z4 is CR16, Z5 is N, and Z6 is CH, (iii) Z4 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X It is O or S(O)x, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring system; R7 is -C(O)R17, -S(O)R18 or -SO2R18; R17 is an alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19, or -NR20R21; where R19 is -OR9 or -NR9R10.Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10. In another embodiment, the compound used in the compositions and methods provided herein has formula Ia: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is H, alkyl, haloalkyl or halogen; and R2 is alkyl, cycloalkyl or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or form a heterocyclic group together with the nitrogen atom to which they are attached; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O or S(O)x, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0059] In another embodiment, the compounds used in the compositions and methods provided herein have formula I or Ia, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is H; and R2 is alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O; R17 is an alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is an alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0060] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is H; and R2 is an alkyl or haloalkyl,Or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is an alkyl group; R11 is an alkoxy group; R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy, or alkyl, and R16 is H, alkyl, alkoxy, halogen, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl, or hydroxymethylalkynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl, or hydroxymethylalkynyl. (See page 37 of CN 122003411 A for details.)

[0061] In another embodiment, the compound used in the compositions and methods provided herein has formula Ia: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is H, alkyl, haloalkyl, or halogen; and R2 is alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16, wherein R16 is H, alkyl, haloalkyl, alkoxy, halogen, alkenyl, or alkynyl; R5 is H, alkyl, haloalkyl, alkoxy, halogen, alkenyl, or alkynyl; X For O, S(O)x or CH2,Where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 is H, alkyl, or haloalkyl; or (ii) Het is a 5- or 6-membered heteroaryl group, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is –C(O)R17 or –SO2R18; R17 represents alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0062] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is H; and R2 is alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R5 is alkenyl or alkynyl; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl, or hydroxymethylalkynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl, or hydroxymethylalkynyl.

[0063] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia,Wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is H; and R2 is alkyl or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R5 is alkynyl; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl.

[0064] In another embodiment, the compound used in the compositions and methods provided herein has Formula I: (See page 39, CN 122003411 A, specification 18 / 253), wherein: a is 0 to 2; R1 is H, alkyl, haloalkyl, or halogen; R2 and R4 together form a heteroalkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12), or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is an alkyl group or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, they form a heterocyclic group; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5.And Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form alkylene or heteroalkylene; X is O, S(O)x or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring system; R7 is -C(O)R17, -S(O)R18, or -SO2R18; Specification 19 / 253, page 40, CN 122003411 A. R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19. Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0065] In another embodiment, the compound used in the compositions and methods provided herein has formula Ia: or a pharmaceutically acceptable derivative thereof,Wherein: a is 0 to 2; R1 is H, alkyl, haloalkyl, or halogen; R2 and R4 together form a heteroalkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12), or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; Z1, Z2, and Z3 are selected from (i) and (ii). Or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl, or haloalkyl; or (ii) R5 and R16 together form an alkylene or heteroalkylene; AX is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is 5-membered or 6-membered. (ii) Het is a 5- or 6-membered heteroaryl group, and R6 is –(CH2)1–2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0066] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R1 is H; R2 and R4 together form -O-(CH2)r- or -O-(CH2)1-3-O-(CH2)1-3-, wherein r is an integer from 2 to 5 and the terminal O is connected to the R4 position of formula I; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is an alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is an alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0067] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R1 is H; R2 and R4 together form -O-(CH2)r- or -O-(CH2)1-3-O-(CH2)1-3-,Where r is an integer from 2 to 5 and the terminal O is connected to the R4 position of Formula I; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; Specification 21 / 253 Page 42 CN 122003411 A R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy or alkyl, and R16 is H, alkyl, alkoxy, halogen or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0068] In another embodiment, the compound used in the compositions and methods provided herein has Formula I: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is H, alkyl, haloalkyl, or halogen; R2 is alkyl, cycloalkyl, or haloalkyl; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N.Or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; Specification 22 / 253 pages 43 CN 122003411 A R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is CR22R23, wherein R22 and R23 are each independently H or alkyl; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het Together with the atoms they are attached to, they form 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R7 is -C(O)R17; and R17 is alkoxy, alkenyloxy, alkynyloxy or -O-(CH2)2-R19; wherein R19 is -OR9 or -NR9R10.

[0069] In another embodiment, the compound used in the compositions and methods provided herein has formula Ia: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is H, alkyl, haloalkyl, or halogen; R2 is alkyl, cycloalkyl, or haloalkyl; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, and one of Z2 and Z3 is C.And the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): Specification 23 / 253 Page 44 CN 122003411 A (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form alkylene or heteroalkylene; X is CR22R23, wherein R22 and R23 are each independently H or alkyl; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het Together with the atoms to which they are attached, they form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17; and R17 is alkoxy, alkenyloxy, alkynyloxy, or -O-(CH2)2-R19; wherein R19 is -OR9 or -NR9R10.

[0070] In another embodiment, the compounds used in the compositions and methods provided herein have formula I or Ia, wherein: R1 is H; R2 is alkyl, cycloalkyl, or haloalkyl; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; X is CH2; and R17 is alkoxy.

[0071] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R1 is H; R2 is alkyl or haloalkyl; R8 is H, CN, OH, aryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; X is CH2; and R17 is alkoxy.

[0072] In one embodiment, a compound of formula II is provided for use in the compositions and methods provided herein: or a pharmaceutically acceptable derivative thereof,Wherein: a is 0 to 2; R1 and R2 together form an alkylene group; Specification 24 / 253 pages 45 CN 122003411 A R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR20R21.

[0073] In one embodiment, a compound of formula IIa is provided for use in the compositions and methods provided herein: (See specification 25 / 253, page 46, CN 122003411 A or a pharmaceutically acceptable derivative thereof), wherein: a is 0 to 2; R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, and one of Z2 and Z3 is C.And the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form alkylene or heteroalkylene; X is O, S(O)x or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring system; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each in their own specification 26 / 253 pages 47 CN 122003411 A R18 is H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR20R21.

[0074] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein: R8 is H, CN, OH, alkoxy, aryl, heteroaryl, NR9R10, or C(O)R11; R9 is H and R10 is H or C(O)R13; wherein R13 is alkyl or alkoxy; and R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl,Or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0075] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein: R8 is H, CN, OH, alkoxy, aryl, NR9R10 or C(O)R11; R9 is H and R10 is C(O)R13; wherein R13 is alkyl; and R11 is alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy or alkyl, and R16 is H, alkyl, alkoxy, halogen or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl.

[0076] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R1 and R2 together form a C2-4 alkylene group.

[0077] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R1 and R2 together form a propylene group.

[0078] In another embodiment, the compound used in the compositions and methods provided herein has formula II: (See specification 27 / 253, page 48, CN 122003411 A) or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii); (i) R1 is an alkyl, cycloalkyl, or haloalkyl; and R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen.Or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2 and Z3 are selected from (i), (ii) or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; Z5 is CR5; Z6 is N or CH; R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, an alkyl, or a haloalkyl; or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het Together with the atoms they are attached to, they form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R 19 or -NR20R21; where R19 is -OR9 or -NR9R10.Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10.

[0079] In another embodiment, the compound used in the compositions and methods provided herein has formula IIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl, cycloalkyl, or haloalkyl; and R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; R5 and R16 together form an alkylene or heteroalkylene group; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is 5 (ii) Het is a 5- or 6-membered heteroaryl group, and R6 is H, an alkyl group, or a haloalkyl group, or (ii) Het is a 5- or 6-membered heteroaryl group, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R 19 or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0080] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl, cycloalkyl, or haloalkyl; and R2 is H or alkoxy, or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0081] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is an alkyl or haloalkyl group; and R2 is H or alkoxy.Or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is an alkyl group; R11 is an alkoxy group; R5 and R16 together form an alkylene group; X is O or CH2; R17 is an alkyl group, haloalkyl group, alkoxy group, alkoxyalkyl group, aminoalkyl group, alkenyl group, haloalkenyl group, ynyl group, or hydroxymethylynyl group; and R18 is an alkyl group, haloalkyl group, alkoxyalkyl group, aminoalkyl group, alkenyl group, haloalkenyl group, ynyl group, or hydroxymethylynyl group. Specification 30 / 253 pages 51 CN 122003411 A

[0082] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R5 and R16 together form a C3-5 alkylene group.

[0083] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R5 and R16 together form a propylidene group.

[0084] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein X is 0 or S(O)x, where x is 0 to 2. In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein X is 0 or S.

[0085] In another embodiment, the compound used in the compositions and methods provided herein has Formula II: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl, cycloalkyl, or haloalkyl, and R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N,One of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5 and Z6 are selected from (i), (ii), (iii) or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O or S(O)x, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms to which they are attached form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is an alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19, or -NR20R21; where R19 is -OR9 or -NR9R10.Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10.

[0086] In another embodiment, the compound used in the compositions and methods provided herein has formula IIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl, cycloalkyl, or haloalkyl, and R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; Specification 32 / 253 pages 53 CN 122003411 A R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O or S(O)x, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl.R6 is –(CH2)1-2-, and R6 and Het together with the atoms they are attached to form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is –C(O)R17 or –SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, –NH-(CH2)2-R19, –O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0087] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl, cycloalkyl, or haloalkyl; and R2 is H or alkoxy, or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0088] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa.Wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is an alkyl or haloalkyl; and R2 is H or alkoxy, or (ii) R1 and R2 together form an alkylene group; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is an alkyl group; R11 is an alkoxy group; R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy or alkyl, and R16 is H, alkyl, alkoxy, halogen or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0089] In another embodiment, the compound used in the compositions and methods provided herein has formula IIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl, cycloalkyl, or haloalkyl, and R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16.Wherein R16 is H, alkyl, haloalkyl, alkoxy, halogen, alkenyl, or alkynyl; R5 is H, alkyl, haloalkyl, alkoxy, halogen, alkenyl, or alkynyl; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is -C(O)R17 or -SO2R18; R17 represents alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0090] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl, cycloalkyl or haloalkyl; and R2 is H or alkoxy,Or (ii) R1 and R2 together form an alkylene group; R5 is alkenyl or alkynyl; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl, or methylalkynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl, or hydroxymethylalkynyl.

[0091] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 is alkyl or haloalkyl; and R2 is H or alkoxy, or (ii) R1 and R2 together form an alkylene group; R5 is alkynyl; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl.

[0092] In another embodiment, the compound used in the compositions and methods provided herein has Formula I: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; R2 and R4 together form a heteroalkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl.Or they may form heterocyclic groups together with the nitrogen atoms to which they are attached; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): Specification 36 / 253 page 57 CN 122003411 A (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N, (ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH, (ii) Z4 is CR16, Z5 is N, and Z6 is CH, (iii) Z4 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form 5,5-, 5,6-, 5,7-, 6,5-, 6,6- Or a 6,7-bicyclic ring system; R7 is -C(O)R17, -S(O)R18 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 or -NR20R21; where R19 is -OR9 or -NR9R10.Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10.

[0093] In another embodiment, the compound used in the compositions and methods provided herein has formula Ia: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; R2 and R4 together form a heteroalkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl, or haloalkyl; or (ii) R5 and R16 together form an alkylene or heteroalkylene group; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 is H, an alkyl group, or a haloalkyl group, or (ii) Het is a 5- or 6-membered heteroaryl group, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0094] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein: R1 is H or alkoxy; R2 and R4 together form -O-(CH2)r- or -O-(CH2)1-3-O-(CH2)1-3-, wherein r is an integer from 2 to 5 and the terminal O is connected to the R4 position of formula I; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0095] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia,Wherein: R1 is H or alkoxy; R2 and R4 together form -O-(CH2)r- or -O-(CH2)1-3-O-(CH2)1-3-, where r is an integer from 2 to 5 and the terminal O is attached to the R4 position of Formula I; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; where R13 is alkyl; R11 is alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy or alkyl, and R16 is H, alkyl, alkoxy, halogen or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0096] In another embodiment, the compound used in the compositions and methods provided herein has formula II: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is alkyl, cycloalkyl, or haloalkyl; R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5,And Z6 is CH, (ii) Z4 is CR16, Z5 is N, and Z6 is CH, (iii) Z4 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is CR22R23, wherein R22 and R23 are each independently H or alkyl; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl. The heteroaryl group has R6 as –(CH2)1-2-, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring system; R7 is –C(O)R17; and R17 is alkoxy, alkenyloxy, alkynyloxy or –O-(CH2)2-R19; wherein R19 is –OR9 or –NR9R10.

[0097] In another embodiment, the compound used in the compositions and methods provided herein has formula IIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is alkyl, cycloalkyl, or haloalkyl; R2 is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O.And Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is CR22R23, wherein R22 and R23 are each independently H or alkyl; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het Together with the atoms to which they are attached, they form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17; and R17 is alkoxy, alkenyloxy, alkynyloxy, or -O-(CH2)2-R19; wherein R19 is -OR9 or -NR9R10.

[0098] In another embodiment, the compounds used in the compositions and methods provided herein have formula II or IIa, wherein: R1 is alkyl, cycloalkyl, or haloalkyl; R2 is H or alkoxy; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; X is CH2; and R17 is alkoxy.

[0099] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein: R1 is an alkyl or haloalkyl; R2 is H or alkoxy; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; X is CH2; and R17 is alkoxy.

[0100] In one embodiment, a compound of formula III is provided for use in the compositions and methods provided herein: or a pharmaceutically acceptable derivative thereof,Wherein: a is 0 to 2; R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2 and Z3 are selected from (i), (ii) or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N; or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, Alkyl, alkenyl, alkynyl, or haloalkyl, or as per specification page 42 / 253, 63 CN 122003411 A (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–,Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR20R21.

[0101] In one embodiment, a compound of formula IIIa is provided for use in the compositions and methods provided herein: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, and one of Z2 and Z3 is C.And the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form alkylene or heteroalkylene; X is O, S(O)x or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring system; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR20R21.

[0102] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein: R8 is H, CN, OH, alkoxy, aryl, heteroaryl, NR9R10, or C(O)R11; R9 is H and R10 is H or C(O)R13; wherein R13 is alkyl or alkoxy; and R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl,Or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0103] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein: R8 is H, CN, OH, alkoxy, aryl, NR9R10, or C(O)R11; R9 is H and R10 is C(O)R13; wherein R13 is alkyl; and R11 is alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy, or alkyl, and R16 is H, alkyl, alkoxy, halogen, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is an alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is an alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0104] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein R1 and R2 together form a C1-4 alkylene group optionally substituted with one or more halogens or methyl groups.

[0105] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein R1 and R2 together form a methylene or ethylene group, each optionally substituted with one or two halogens or methyl groups. In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein R1 and R2 together form an unsubstituted methylene or ethylene group.

[0106] In another embodiment, the compound used in the compositions and methods provided herein has Formula III: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl, cycloalkyl, or haloalkyl,Or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2 and Z3 are selected from (i), (ii) or (iii): Specification 45 / 253 Page 66 CN 122003411 A (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; Z5 is CR5; Z6 is N or CH; R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het Together with the atoms they are attached to, they form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; where R19 is -OR9 or -NR9R10,Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10.

[0107] In another embodiment, the compound used in the compositions and methods provided herein has formula IIIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is CR16; R5 and R16 together form an alkylene or heteroalkylene group; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is 5 (ii) Het is a 5- or 6-membered heteroaryl group, and R6 is H, an alkyl group, or a haloalkyl group, or (ii) Het is a 5- or 6-membered heteroaryl group, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0108] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each alkyl, or (ii) R1 and R2 together form an alkylene group optionally substituted with one or more halogens or methyl groups; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and specification 47 / 253 pages 68 CN 122003411 A R18 is an alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0109] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein R5 and R16 together form a C3-5 alkylene group.

[0110] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein R5 and R16 together form a propylidene group.

[0111] In another embodiment,The compounds used in the compositions and methods provided herein have formula III or IIIa, wherein X is O or S(O)x, and x is 0 to 2. In another embodiment, the compounds used in the compositions and methods provided herein have formula III or IIIa, wherein X is O or S.

[0112] In another embodiment, the compound used in the compositions and methods provided herein has Formula III: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is an alkyl group or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, forming a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5, and Z6 are selected from (i), (ii), (iii), or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH. (See specification 48 / 253 pages, 69 CN 122003411) A (iii) Z4 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, alkynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O or S(O)x,Where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 is H, alkyl, or haloalkyl; or (ii) Het is a 5- or 6-membered heteroaryl group, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is –C(O)R17, –S(O)R18, or –SO2R18; R17 represents alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0113] In another embodiment, the compound used in the compositions and methods provided herein has formula IIIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl, or C(O)R13; wherein R13 is alkyl, alkoxy, or NR14R15; Specification 49 / 253 pages 70 CN 122003411 A R11 is hydroxyl, alkyl, alkoxy, or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl.Or together with the nitrogen atom to which they are attached, they form a heterocyclic group; R4 is H or alkoxy; Z1, Z2 and Z3 are selected from (i), (ii) or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N, (ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O or S(O)x, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R6 is H, alkyl, or haloalkyl; or (ii) Het is a 5- or 6-membered heteroaryl group, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring system; R7 is –C(O)R17 or –SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, Methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0114] In another embodiment, the compounds used in the compositions and methods provided herein have formula III or IIIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each alkyl,Or (ii) R1 and R2 together form an alkylene group optionally substituted with one or more halogens or methyl groups; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl, or as per specification page 50 / 253, page 71, CN 122003411 A; (ii) R5 and R16 together form an alkylene group; X is O; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0115] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each alkyl, or (ii) R1 and R2 together form an alkylene group optionally substituted with one or more halogens or methyl groups; R8 is H, CN, OH, aryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy, or alkyl, and R16 is H, alkyl, alkoxy, halogen, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0116] In another embodiment, the compound used in the compositions and methods provided herein has formula IIIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl, cycloalkyl, or haloalkyl,Or (ii) R1 and R2 together form an alkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); Specification 51 / 253 pages 72 CN 122003411 A R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached form a heterocyclic group; R4 is H or alkoxy; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4 is N or CR16, wherein R16 is H, alkyl, haloalkyl, alkoxy, halogen, alkenyl, or alkynyl; R5 is H, alkyl, haloalkyl, alkoxy, halogen, alkenyl, or alkynyl; X is O, S(O)x, or CH2, wherein x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl; or (ii) Het is a 5- or 6-membered heteroaryl. The heteroaryl group has R6 as –(CH2)1-2-, and R6 and Het together with the atoms they are attached to form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is –C(O)R17 or –SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; where R19 is -OR9 or -NR9R10,Furthermore, R20 and R21 are each independently H, alkyl, cycloalkyl, or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR9R10.

[0117] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl, cycloalkyl, or haloalkyl, or (ii) R1 and R2 together form an alkylene group optionally substituted with one or more halogens or methyl groups; R5 is alkenyl or alkynyl; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl, or hydroxymethylalkynyl; and specification 52 / 253 pages 73 CN 122003411 A R18 is an alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0118] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein: R1 and R2 are selected from (i) or (ii): (i) R1 and R2 are each independently alkyl or haloalkyl, or (ii) R1 and R2 together form an alkylene group optionally substituted with one or more halogens or methyl groups; R5 is alkynyl; R8 is H, CN, OH, aryl, NR9R10 or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl; R11 is alkoxy; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, alkynyl or hydroxymethylalkynyl.

[0119] In another embodiment, the compound used in the compositions and methods provided herein has Formula III: or a pharmaceutically acceptable derivative thereof,Wherein: a is 0 to 2; R1 is alkyl or haloalkyl; R2 and R4 together form a heteroalkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; Z1, Z2 and Z3 are selected from (i), (ii) or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C, or (iii) Z1 is CH, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; Z4, Z5 and Z6 are selected from (i), (ii), (iii) or (iv): (i) Z4 is N, Z5 is CR5, and Z6 is CH; (ii) Z4 is CR16, Z5 is N, and Z6 is CH; (iii) Z4 is CR16, Z5 is CR5, and Z6 is N, or (iv) Z4 is CR16, Z5 is CR5, and Z6 is CH; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R5 and R16 together form an alkylene or heteroalkylene; X is O, S(O)x, or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl, and R6 is H, alkyl, or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl, and R6 is –(CH2)1-2–.Furthermore, R6 and Het, together with the atoms they are attached to, form 5,5-, 5,6-, 5,7-, 6,5-, 6,6-, or 6,7- bicyclic ring systems; R7 is -C(O)R17, -S(O)R18, or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0120] In another embodiment, the compound used in the compositions and methods provided herein has formula IIIa: or a pharmaceutically acceptable derivative thereof, wherein: a is 0 to 2; R1 is alkyl or haloalkyl; R2 and R4 together form a heteroalkylene group; R3 is -O-(CH2)b-R8; b is 1 to 4; R8 is H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, NR9R10, C(O)R11, C(=NH)(R12) or C(=N-O-R9)(R12); R9 and R10 are each independently H, alkyl or C(O)R13; wherein R13 is alkyl, alkoxy or NR14R15; R11 is hydroxyl, alkyl, alkoxy or NR14R15; R12 is alkyl or NR14R15; R14 and R15 are each independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; Z1, Z2, and Z3 are selected from (i), (ii), or (iii): (i) Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; (ii) Z1 is NH or O, and Z2 and Z3 are C; or (iii) Z1 is CH, and one of Z2 and Z3 is C.And the other of Z2 and Z3 is N; Z4 is N or CR16; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, alkynyl or haloalkyl, or (ii) R5 and R16 together form alkylene or heteroalkylene; X is O, S(O)x or CH2, where x is 0 to 2; Het and R6 are selected from (i) or (ii): (i) Het is 5- or 6-membered heteroaryl, and R6 is H, alkyl or haloalkyl, or (ii) Het is 5- or 6-membered heteroaryl, R6 is –(CH2)1-2–, and R6 and Het together with the atoms they are attached to form a 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring system; R7 is -C(O)R17 or -SO2R18; R17 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R19, -O-(CH2)2-R19 Or -NR20R21; wherein R19 is -OR9 or -NR9R10, and R20 and R21 are each independently H, alkyl, cycloalkyl or haloalkyl; and R18 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl or -NR9R10.

[0121] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein: R1 is alkyl; R2 and R4 together form -O-(CH2)r- or -O-(CH2)1-3-O-(CH2)1-3-,Where r is an integer from 2 to 5 and the terminal O is attached to the R4 position of formula III or IIIa; R8 is H, CN, OH, aryl, heteroaryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is alkyl or alkoxy; R11 is alkyl or alkoxy; R5 and R16 are selected from (i) or (ii): (i) R5 and R16 are each independently H, cyano, halogen, alkoxy, alkyl, alkenyl, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

[0122] In another embodiment, the compound used in the compositions and methods provided herein has formula III or IIIa, wherein: R1 is an alkyl group; R2 and R4 together form -O-(CH2)r- or -O-(CH2)1-3-O-(CH2)1-3-, wherein r is an integer from 2 to 5 and the terminal O is attached to the R4 position of formula III or IIIa; R8 is H, CN, OH, aryl, NR9R10, or C(O)R11; R9 and R10 are each independently H or C(O)R13; wherein R13 is an alkyl group; R11 is an alkoxy group; R5 and R16 are selected from (i) or (ii): (i) R5 is H, cyano, alkoxy, or alkyl, and R16 is H, alkyl, alkoxy, halogen, or alkynyl, or (ii) R5 and R16 together form an alkylene group; X is O or CH2; R17 is alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R18 is alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl.

[0123] In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein X is O. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein X is CH2.

[0124] In another embodiment, a is 0. In another embodiment, a is 1. In another embodiment, a is 2. In another embodiment,a is 0 or 1.

[0125] In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R2 is an alkyl group. In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R2 is methyl. In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R2 is a haloalkyl group. In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R2 is fluoromethyl, difluoromethyl, or trifluoromethyl. In another embodiment, the compound used in the compositions and methods provided herein has formula I or Ia, wherein R2 is difluoromethyl.

[0126] In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R2 is H. In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R2 is an alkoxy group. In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R2 is methoxy. In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R2 is haloalkoxy. In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R2 is fluoromethoxy, difluoromethoxy, or trifluoromethoxy. In another embodiment, the compound used in the compositions and methods provided herein has formula II or IIa, wherein R2 is difluoromethoxy.

[0127] In another embodiment, b is 1. In another embodiment, b is 2. In another embodiment, b is 3. In another embodiment, b is 4. In another embodiment, b is 1 or 2.

[0128] In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R8 is H, phenyl, 4-fluorophenyl, morpholino, COOH, COOMe, C(=NH)NHOH, tetrazolyl, oxadiazolyl, triazolyl, pyridyl, imidazolyl, oxazolidinyl, NHC(O)OMe, cyano, hydroxyl, amino, or acetamino. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R8 is H, phenyl, COOMe, hydroxyl, cyano, amino, or acetamino. In another embodiment,The compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein R8 is hydrogen. In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein b is 1 and R8 is hydrogen.

[0129] In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein R4 is alkoxy. In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein R4 is methoxy. In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein R4 is H.

[0130] In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein Z1 is NH or O, and Z2 and Z3 are C. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein Z1 is O, and Z2 and Z3 are C.

[0131] In another embodiment, Z4 is N. In another embodiment, Z4 is CR16.

[0132] In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R5 is H, cyano, alkoxy, or alkyl, and R16 is H, alkyl, alkoxy, halogen, or alkynyl. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R5 is H, cyano, methoxy, or methyl, and R16 is H, methyl, ethyl, isopropyl, tert-butyl, methoxy, chlorine, fluorine, ethynyl, or propynyl. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R5 is H, cyano, methoxy, or methyl, and R16 is H, methyl, ethyl, isopropyl, tert-butyl, methoxy, chloro, ethynyl, or propynyl. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R5 is H and R16 is H, methyl, ethyl, isopropyl, tert-butyl, or methoxy.

[0133] In another embodiment,The compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein Het is a 5- or 6-membered heteroaryl group, and R6 is H or an alkyl group. In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein Het is a 5-membered heteroaryl group, and R6 is H or a methyl group. In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein Het is pyrazolyl, oxazolyl, thiazolyl, or pyridinyl, and R6 is H or a methyl group. In another embodiment, the compounds used in the compositions and methods provided herein (see page 57 / 253, CN 122003411 A) have formula I, Ia, II, IIa, III, or IIIa, wherein Het is pyrazolyl, and R6 is H or a methyl group. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein Het is a 5- or 6-membered heteroaryl group, R6 is –(CH2)1–2–, and R6 and Het, together with the atoms to which they are attached, form a 5,5–, 5,6–, 5,7–, 6,5–, 6,6–, or 6,7–bicyclic ring system. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein Het is a 5-membered heteroaryl group, R6 is –(CH2)–, and R6 and Het, together with the atoms to which they are attached, form a 5,5–bicyclic ring system. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein Het is a pyrazolyl group, R6 is –(CH2)–, and R6 and Het together with the atoms to which they are attached form a 5,5-bicyclic ring system.

[0134] In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R7 is –C(O)R17. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R7 is –S(O)R18. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R7 is –SO2R18. In another embodiment,The compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein R17 is alkyl, alkoxy, alkenyl, haloalkenyl, alkynyl, NR20R21, or hydroxyalkynyl. In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein R17 is alkyl, alkoxy, alkenyl, haloalkenyl, alkynyl, or hydroxyalkynyl. In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein R17 is methyl, methoxy, NHMe, vinyl, 1-fluoro-1-vinyl, ethynyl, or 1-propynyl-1-yl. In another embodiment, the compounds used in the compositions and methods provided herein have formula I, Ia, II, IIa, III, or IIIa, wherein R17 is methyl, methoxy, vinyl, 1-fluoro-1-vinyl, ethynyl, or 1-propynyl-1-yl. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R17 is methyl or methoxy. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R17 is methoxy. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R17 is vinyl, 1-fluoro-1-vinyl, ethynyl, or 1-propynyl-1-yl. In another embodiment, the compound used in the compositions and methods provided herein has formula I, Ia, II, IIa, III, or IIIa, wherein R18 is methyl or tert-butyl.

[0135] In another embodiment, the compound used in the compositions and methods provided herein is selected from: Specification 58 / 253 page 79 CN 122003411 A In another embodiment, the compound used in the compositions and methods provided herein is selected from: , , , and.

[0136] In another embodiment, the compounds used in the compositions and methods provided herein are selected from: Specification 59 / 253 pages 80 CN 122003411 A In another embodiment, the compounds used in the compositions and methods provided herein are selected from: In another embodiment,The compounds used in the compositions and methods provided herein are selected from: , , , , , , , , Specification 60 / 253 page 81 CN 122003411 A , , , , , , , , , , , , , , , , , , Specification 61 / 253 page 82 CN 122003411 A , , , , , , , , , , , , , , Specification 62 / 253 page 83 CN 122003411 A , , .

[0137] In another embodiment, the compounds used in the compositions and methods provided herein are: , , , , , , , , , or.

[0138] In another embodiment, the compounds used in the compositions and methods provided herein are: , , , , , , , , or.

[0139] In another embodiment, the compounds used in the compositions and methods provided herein are: , or.

[0140] In another embodiment, the compounds used in the compositions and methods provided herein are: , ...

[0143] Other steps and reagents not provided in the exemplary preparation methods will be known to those skilled in the art. Exemplary preparation methods are described in detail in the examples herein.

[0144] General Scheme 1 describes the preparation of a compound of Formula I, wherein Z1 is O and Z2 and Z3 are C; and all other groups are as defined in the summary of the invention or in any of the examples described herein.

[0145] General Scheme 1 outlines a method for preparing a suitably substituted benzo[d]isoxazole compound provided herein, wherein in step 1, a suitably substituted 2-fluorobenzonitrile is converted to a benzo[d]isoxazole-3-amine scaffold by reacting it with N-hydroxyacetamide in the presence of a base such as potassium tert-butoxide. In step 2, the free amine is reacted with an aryl or heteroaryl sulfonyl chloride in the presence of a base such as sodium tert-amyloxide, triethylamine, pyridine, or sodium hydride. This can be done at 0°C.However, the specification, page 65 / 253, 86 CN 122003411 A, may need to be completed at room temperature or high temperature (such as 60°C). The final step includes the deprotection of the amine (step 3), followed by the formation of an amide in step 4 (via reaction with a suitably substituted acyl chloride or via activation of the acid using a coupling agent such as HATU, HBTU, T3P, EDCI / HOBt or other reagents known to those skilled in the art) or the formation of a sulfonamide with a sulfonyl chloride in the presence of a base such as triethylamine. To prepare carbamates or urea derivatives, a suitably substituted chloroformate or isocyanate may be reacted with a free amine in the presence of a base such as triethylamine.

[0146] General scheme 2 describes the preparation of compounds of formula I, wherein Z1 and Z3 are N and Z2 is C; and all other groups are as defined in the summary of the invention or any of the examples described herein.

[0147] As shown, the [1,2,4]triazolo[4,3-a]pyridine compounds provided herein can be prepared by starting with a suitably substituted 2-chloropyridine, which can be converted to the corresponding 2-hydrazinopyridine by heating in the presence of hydrazine hydrate (step 1). In step 2, reaction with cyanogen bromide causes the assembly of the [1,2,4]triazolo[4,3-a]pyridine-3-amine scaffold. Steps 3, 4, and 5 follow the scheme detailed above with respect to general scheme 1 (steps 2, 3, and 4), thereby synthesizing compound I, wherein Z1 and Z3 are N and Z2 is C.

[0148] General scheme 3 describes the preparation of compound I, wherein Z1 and Z2 are N and Z3 is C; and all other groups are as defined in the summary of the invention or any of the examples described herein.

[0149] Appropriately substituted 2-cyanopyridine is converted to 1-amino-2-cyanopyridine by reacting with sulfonated hydroxylamine or (aminooxy)sulfonic acid (step 1, condition A or B), followed by cyclization in the presence of hydroxylamine and acetic anhydride (step 2). Steps 3, 4 and 5 follow the scheme detailed above with respect to general scheme 1 (steps 2, 3 and 4), thereby synthesizing compound of formula I, wherein Z1 and Z2 are N and Z3 is C. Specification 66 / 253 pages 87 CN 122003411 A

[0150] General scheme 4 describes the preparation of compound of formula I, wherein Z1 is NH and Z2 and Z3 are C; and all other groups are as defined in the summary of the invention or any of the examples described herein.

[0151] As shown above,The appropriately substituted 2-fluorobenzonitrile starting material is converted to 3-aminobenzopyrazole using hydrazine in the presence of a base such as potassium carbonate (step 1). Steps 2, 3, and 4 follow the scheme detailed above with respect to general scheme 1 (steps 2, 3, and 4), thereby synthesizing compound of formula I, wherein Z1 is NH and Z2 and Z3 are C.

[0152] General scheme 5 describes the preparation of compound of formula I, wherein Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N; and all other groups are as defined in the summary of the invention or in any of the examples described herein.

[0153] General scheme 5(A) shows that in step 1, the appropriately substituted pyridinecarboxynitrile is reduced with LAH in a solvent such as THF. The resulting 2-aminomethylpyridine intermediate is treated with cyanide bromide in toluene (step 2) to give imidazo[1,5-a]pyridine-3-amine intermediate A. In general scheme 5(B), a suitably substituted 2-cyanopyridine is reduced to the corresponding 2-aminomethylpyridine (as in step 1 of scheme 5A above), followed by steps 2 and 3, which include N-formylation, and then reflux in phosphoryl chloride to construct an imidazo[1,5-a]pyridine ring. Nitration and reduction with the reagent in step 4 yield the substituted imidazo[1,5-a]pyridine-1-amine intermediate B. In the final step, intermediates A and B follow the scheme detailed above in scheme 1 (steps 2, 3, and 4) on page 67 / 253 of the general specification, CN 122003411, thereby synthesizing compound I, wherein Z1 is N, one of Z2 and Z3 is C, and the other of Z2 and Z3 is N.

[0154] General Scheme 6 describes the preparation of the compound of Formula I, wherein R2 and R4 together form a heteroalkylene group; and all other groups are as defined in the summary of the invention or in any of the embodiments described herein.

[0155] The synthesis of the macrocyclic compound is accomplished by assembling the starting materials using the general method described above. In General Scheme 6 (A), R4 is a phenoxy or heteroaryloxy group having a terminal leaving group, which reacts with the hydroxyl group at R2 in the presence of a base such as NaH or K2CO3. Alternatively, in General Scheme 6 (B), R4 is a phenoxy or heteroaryloxy group having a terminal olefin, which reacts with the terminal olefin at R2 in a ring-closed metathesis (RCM) reaction in the presence of a Grubb catalyst. The resulting olefin is characteristic of the final molecule or is reduced to a saturated heterocycle. Steps 2 and 3 follow the scheme detailed above with respect to General Scheme 1 (steps 2, 3, and 4), thereby synthesizing the compound of Formula I.R2 and R4 form a heteroalkylene group.

[0156] IV. Pharmaceutical Compositions The pharmaceutical compositions provided herein contain a therapeutically effective amount of one or more of the compounds provided herein and a pharmaceutically acceptable carrier, diluent, or excipient.

[0157] The compound can be formulated into suitable pharmaceutical formulations, such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained-release formulations, or elixirs for oral administration or for ophthalmic or parenteral administration in a sterile solution or suspension, as well as transdermal patch formulations and dry powder inhalers. Typically, the above-described compounds are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see, for example, Ansel Introduction to Pharmaceutical Dosage Forms, 7th Edition 1999).

[0158] In the composition, an effective concentration of one or more compounds or a pharmaceutically acceptable salt is mixed with a suitable pharmaceutical carrier or solvent. In some embodiments, the concentration of the compound in the composition is effective for delivering an amount that treats, prevents, or improves one or more symptoms and / or progression of the disease or condition disclosed herein at the time of administration. Instructions for Use, Pages 68 / 253, 89, CN 122003411 A

[0159] Typically, compositions are formulated for single-dose administration. To formulate a composition, a weight fraction of the compound is dissolved, suspended, dispersed, or otherwise mixed in a selected solvent at an effective concentration such that the condition is relieved or improved. Suitable drug carriers or solvents for administering the compounds provided herein include any such carriers known to those skilled in the art as suitable for a particular mode of administration.

[0160] Furthermore, the compound may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients. Liposome suspensions, including tissue-targeting liposomes, such as tumor-targeting liposomes, may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. For example, liposome formulations may be prepared as known in the art. Briefly, liposomes such as multilayer vesicles (MLVs) may be formed by drying the inside of a flask with lecithin choline and cephalin acylserine (7:3 molar ratio). Add a solution of the compound provided herein in phosphate-buffered saline (PBS) lacking divalent cations, and shake the flask until the lipid membrane disperses. Wash the resulting vesicles to remove unencapsulated compound, granulate by centrifugation, and then resuspend in PBS.

[0161] The active compound is contained in a pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect on the treated subject in the absence of undesirable side effects. Therapeuticly effective concentrations can be determined empirically by testing the compound in the in vitro and in vivo systems described herein and then extrapolating the human dose from thereto. In some embodiments,The active compound is administered in a manner that achieves a therapeutically effective concentration of the drug. In some embodiments, companion diagnostics (see, for example, Olsen D and Jorgensen JT, Front. Oncol., May 16, 2014, 4:105, doi: 10.3389 / fonC.2014.00105) are used to determine the therapeutic concentration and safety profile of the active compound in a particular subject or subject population.

[0162] The concentration of the active compound in the pharmaceutical composition will depend on the absorption, tissue distribution, inactivation and excretion rate of the active compound, the physicochemical properties of the compound, the dosing schedule and the amount administered, and other factors known to those skilled in the art. For example, the amount delivered is sufficient to improve one or more symptoms of the disease or condition disclosed herein.

[0163] In some embodiments, the therapeutically effective dose should produce a serum concentration of the active ingredient of about 0.1 ng / mL to about 50 to 100 µg / mL. In one embodiment, the pharmaceutical composition provides a dose of about 0.001 mg to about 2000 mg of the compound per kilogram of body weight per day. Pharmaceutical dosage units are prepared to provide about 1 mg to about 1000 mg per dosage unit, and in some embodiments about 10 mg to about 500 mg of the essential active ingredient or combination of essential ingredients.

[0164] The active ingredient may be administered once or may be divided into multiple smaller doses administered at time intervals. It should be understood that the exact dose and duration of treatment are a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It should be noted that concentration and dose values ​​may also vary with the severity of the condition to be relieved. It should be further understood that, for any particular subject, the specific dosage regimen should be adjusted over time according to individual needs and the professional judgment of the person administering the composition or supervising the administration of the composition, and the concentration ranges listed herein are merely exemplary and are not intended to limit the scope or practice of the claimed compositions.

[0165] Thus, an effective concentration or amount of one or more of the compounds described herein or their pharmaceutically acceptable salts are mixed with a suitable pharmaceutical carrier or solvent for systemic, topical, or local administration to form a pharmaceutical composition. The compound is included in an amount that effectively improves one or more symptoms, or is used for treatment, delaying progression, or prevention. The concentration of the active compound in the composition will depend on absorption, tissue distribution, inactivation, the rate of excretion of the active compound, the dosing schedule, the amount administered, the specific formulation, and other factors known to those skilled in the art.

[0166] The composition is intended to be administered via a suitable route, including but not limited to oral, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, mucosal, skin, transdermal, oral, rectal, topical, nasal, or inhalation. For oral administration,Capsules and tablets can be formulated according to the instructions on page 69 / 253, 90 CN 122003411 A. The composition is in liquid, semi-liquid, or solid form and is formulated in a manner suitable for each route of administration.

[0167] Solutions or suspensions for parenteral, intradermal, subcutaneous, or topical application may include any of the following components: sterile diluents, such as water for injection, saline solution, fixative oil, polyethylene glycol, glycerol, propylene glycol, dimethylacetamide, or other synthetic solvents; antimicrobial agents, such as benzyl alcohol and methylparaben; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates, and phosphates; and agents for adjusting tension, such as sodium chloride or glucose. Parenteral formulations may be packaged in ampoules, pens, disposable syringes, or single- or multi-dose vials made of glass, plastic, or other suitable materials.

[0168] In cases where the compound exhibits insufficient solubility, methods for solubilizing the compound may be used. Such methods are known to those skilled in the art and include, but are not limited to, the use of cosolvents such as dimethyl sulfoxide (DMSO), the use of surfactants such as TWEEN®, or dissolution in an aqueous sodium bicarbonate solution.

[0169] When the compound is mixed or added, the resulting mixture may be a solution, suspension, emulsion, etc. The form of the resulting mixture depends on many factors, including the intended method of administration and the solubility of the compound in the selected carrier or solvent. An effective concentration sufficient to improve the symptoms of the disease, condition, or illness being treated can be determined empirically.

[0170] Pharmaceutical compositions are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions and oral solutions or suspensions and oil-water emulsions containing an appropriate amount of the compound or a pharmaceutically acceptable salt thereof. Therapeutic compounds and their salts are formulated and administered in unit dosage forms or multiple dosage forms. As used herein, a unit dosage form refers to a physically separated unit suitable for human and animal subjects and individually packaged as known in the art. Each unit dose contains a predetermined amount of a therapeutically active compound, sufficient to produce the desired therapeutic effect, associated with a desired drug carrier, solvent, or diluent. Examples of unit dosage forms include ampoules and syringes, as well as individually packaged tablets or capsules. A unit dosage form can be a portion or multiple unit dosage forms of a unit dosage form. A multi-dosage form is multiple identical unit dosage forms packaged in a single container for administration in separate unit dosage forms. Examples of multi-dosage forms include vials, bottles of tablets or capsules, or pints or gallons. Thus, a multi-dosage form is multiple unit doses not separated in the package.

[0171] Sustained-release preparations can also be prepared. Suitable examples of sustained-release formulations include a semi-permeable matrix of a solid hydrophobic polymer containing the compounds provided herein.The matrix is ​​in the form of a molded article, such as a membrane or microcapsule. Examples of sustained-release matrices include iontophoresis patches, polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol)), polylactide, copolymers of L-glutamic acid and ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic-glycolic acid copolymers such as LUPRON DEPOT™ (injectable microspheres composed of lactic-glycolic acid copolymers and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic-glycolic acid enable the release of molecules for more than 100 days, some hydrogels release proteins in a shorter time. When encapsulated compounds remain in the body for extended periods, they may denature or aggregate due to exposure to moisture at 37°C, leading to loss of bioactivity and potential structural changes. Appropriate stabilization strategies can be designed depending on the mechanism of action involved. For example, if the aggregation mechanism is found to be the formation of intermolecular S-S bonds through thiodisulfide exchange, stabilization can be achieved by modifying thiol residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

[0172] Dosage forms or compositions containing 0.005% to 100% of the active ingredient and the balance consisting of a non-toxic carrier can be prepared. For oral administration, pharmaceutically acceptable non-toxic compositions are formed by incorporating any of commonly used excipients, such as, for example, pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, talc, cellulose derivatives, croscarmellose sodium, glucose, sucrose, magnesium carbonate, or sodium saccharin. Such compositions include solutions, suspensions, tablets, capsules, powders, and sustained-release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable biocompatible polymers such as collagen, ethylene-vinyl acetate, polyanhydride, polyglycolic acid, polyorthoester, polylactic acid, etc. Methods for preparing these compositions are known to those skilled in the art. The intended compositions may contain from about 0.001% to 100% of the active ingredient, in some embodiments from about 0.1% to 85% of the active ingredient, or in other embodiments from about 75% to 95% of the active ingredient.

[0173] The active compound or pharmaceutically acceptable salt may be prepared with a carrier that protects the compound from rapid elimination from the body, such as a time-release formulation or coating.

[0174] The composition may include other active compounds to obtain the desired combination of properties. The compounds described herein, or their pharmaceutically acceptable salts as described herein, may also be advantageously administered in combination with another pharmacological agent known in the art for therapeutic or preventative purposes.This other pharmacological agent is valuable for treating one or more of the diseases or medical conditions mentioned above, such as those related to oxidative stress. It should be understood that such combination therapy constitutes another aspect of the compositions and treatments provided herein.

[0175] The lactose-free compositions provided herein may contain excipients well known in the art and listed, for example, in the United States Pharmacopeia (USP) SP (XXI) / NF (XVI). Generally, lactose-free compositions contain pharmaceutically compatible and pharmaceutically acceptable amounts of active ingredients, binders / fillers, and lubricants. Exemplary lactose-free dosage forms contain active ingredients, microcrystalline cellulose, pregelatinized starch, and magnesium stearate.

[0176] Further comprising anhydrous pharmaceutical compositions and dosage forms containing compounds provided herein. For example, the addition of water (e.g., 5%) is widely accepted in the pharmaceutical field as a means of simulating long-term storage to determine properties such as shelf life or the stability of the formulation over time. See, for example, Jens T. Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80. In fact, water and heat accelerate the decomposition of some compounds. Therefore, the effect of water on formulations can be significant because they are typically exposed to moisture and / or humidity during the manufacture, handling, packaging, storage, transport, and use of the formulation.

[0177] The anhydrous pharmaceutical compositions and dosage forms provided herein can be prepared using anhydrous or low-aqueous components and under low-moisture or low-humidity conditions. Pharmaceutical compositions and dosage forms containing lactose and at least one active ingredient containing a primary or secondary amine are anhydrous if substantial contact with moisture and / or damp heat is anticipated during manufacture, packaging, and / or storage.

[0178] Anhydrous pharmaceutical compositions should be prepared and stored such that they retain their anhydrous properties. Therefore, anhydrous compositions are packaged using materials known to prevent exposure to water so that they can be included in suitable formulation kits. Examples of suitable packaging include, but are not limited to, gas-sealed foil, plastic, unit-dose containers (e.g., vials), blister packs, and strip packs.

[0179] A. Oral Dosage Forms Oral drug dosage forms are solid, gel, or liquid. Solid dosage forms include tablets, capsules, granules, and powders. Types of oral tablets include compressed, chewable tablets, and tablets that may be enteric-coated, sugar-coated, or film-coated. Capsules may be hard or soft gelatin capsules, while granules and powders may be provided in non-effervescent or effervescent forms in combination with other ingredients known to those skilled in the art.

[0180] In some embodiments, the formulation is a solid dosage form.Such as capsules or tablets. Tablets, pills, capsules, sugar tablets, etc., may contain any of the following ingredients or compounds with similar properties: binders; diluents; disintegrants; lubricants; gliding agents; sweeteners and flavorings.

[0181] Examples of binders include microcrystalline cellulose, astragalus gum, glucose solution, gum arabic paste, gelatin solution, sucrose and starch paste. Lubricants include talc, starch, magnesium stearate or calcium stearate, phycocyanin and stearic acid. Diluents include, for example, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate. Gliding agents include, but are not limited to, colloidal silica. Disintegrants include croscarmellose sodium, starch glycolate sodium, croscarmellose, alginate, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. Colorants include, for example, any of the following: approved, certified water-soluble FD and C dyes, mixtures thereof; and water-insoluble FD and C dyes suspended on hydrated alumina. Sweeteners include sucrose, lactose, mannitol, and artificial sweeteners such as saccharin and any number of spray-dried flavorings. Flavorings include natural flavorings extracted from plants such as fruits and synthetic mixtures of compounds that produce a pleasant sensation, such as, but not limited to, peppermint and methyl salicylate. Wetting agents include propylene glycol monostearate, sorbitol monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Enteric coatings include fatty acids, fats, waxes, shellac, ammoniated shellac, and cellulose acetate phthalate. Film coatings include hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol 4000, and cellulose acetate phthalate.

[0182] If oral administration is required, the compounds may be provided in the form of compositions that protect them from the acidic environment of the stomach. For example, the composition can be formulated with an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition can also be formulated in combination with antacids or other such ingredients.

[0183] When the dosage unit is in capsule form, it may contain a liquid carrier such as fatty oil in addition to the materials of the types described above. Furthermore, the dosage unit form may contain various other materials that alter the physical form of the dosage unit, such as sugar coatings and other enteric solvents. The compound can also be administered as a component of elixirs, suspensions, syrups, wafers, chewing gums, etc. In addition to the active compound, syrups may also contain sucrose as a sweetener and certain preservatives, dyes and colorants, and flavorings.

[0184] The active material can also be mixed with other active materials that do not impair the desired effect, or with materials that complement the desired effect.Examples include antacids, H2 blockers, and diuretics. The active ingredient is a compound as described herein or a pharmaceutically acceptable salt thereof. Higher concentrations of the active ingredient, up to about 98% by weight, may be included.

[0185] Pharmaceutically acceptable carriers included in tablets are binders, lubricants, diluents, disintegrants, colorants, flavorings, and wetting agents. Enteric-coated tablets resist the action of gastric acid and dissolve or disintegrate in a neutral or alkaline intestine due to enteric coating. Sugar-coated tablets are compressed tablets to which different layers of pharmaceutically acceptable substances may be applied. Film-coated tablets are compressed tablets already coated with a polymer or other suitable coating. Recompressed tablets are compressed tablets prepared using the pharmaceutically acceptable substances mentioned above through more than one compression cycle. Colorants may also be used in the above dosage forms. Flavorings and sweeteners are used in compressed tablets, sugar-coated tablets, recompressed tablets, and chewable tablets. Flavorings and sweeteners are particularly useful in the formation of chewable tablets and lozenges.

[0186] Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions, and / or suspensions reconstituted from non-effervescent particles, as well as effervescent formulations reconstituted from effervescent particles. Aqueous solutions include, for example, elixirs and syrups. Emulsions are either oil-in-water or water-in-oil. In some embodiments, suspensions are suspensions of microparticles or nanoparticles. In some embodiments, emulsions are emulsions of microparticles or nanoparticles.

[0187] Elixirs are clear, sweet aqueous alcoholic formulations. Pharmaceutically acceptable carriers for elixirs include solvents. Syrups are concentrated aqueous solutions of sugars such as sucrose and may contain preservatives. Emulsions are two-phase systems.One liquid is dispersed in another liquid in the form of small spheres. Pharmaceutically acceptable carriers for emulsions are non-aqueous liquids, emulsifiers, and preservatives. Suspensions use pharmaceutically acceptable suspending agents and preservatives. Pharmaceutically acceptable substances for non-effervescent granules to be reconstituted into a liquid oral dosage form include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable substances for effervescent granules to be reconstituted into a liquid oral dosage form include organic acids and carbon dioxide sources. Colorants and flavoring agents are used in all the above dosage forms.

[0188] Solvents include glycerol, sorbitol, ethanol, and syrups. Examples of preservatives include glycerol, methylparaben and propylparaben, benzoic acid, sodium benzoate, and alcohols. Examples of non-aqueous liquids for emulsions include mineral oil and cottonseed oil. Examples of emulsifiers include gelatin, gum arabic, astragalus gum, bentonite, and surfactants such as polyoxyethylene dehydrated sorbitol monooleate. The suspending agents include sodium carboxymethyl cellulose, pectin, astragalus gum, veegum, and gum arabic. The diluents include lactose and sucrose. The sweeteners include sucrose, syrup, glycerin, and artificial sweeteners such as saccharin. The wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. The organic additives include citric acid and tartaric acid. The carbon dioxide sources include sodium bicarbonate and sodium carbonate. The colorants include any of the approved, certified water-soluble FD and C dyes and mixtures thereof. The flavoring agents include natural flavorings extracted from plants such as fruits and synthetic mixtures of compounds that produce a pleasant taste.

[0189] For solid dosage forms, a solution or suspension (e.g., propylene carbonate, vegetable oil, or triglycerides) is encapsulated in a gelatin capsule. Such solutions and their preparation and encapsulation are disclosed in U.S. Patent Nos. 4,328,245, 4,409,239, and 4,410,545. For liquid dosage forms, solutions, such as those in polyethylene glycol, may be diluted with a sufficient amount of a pharmaceutically acceptable liquid carrier (e.g., water) to facilitate measurement for administration.

[0190] Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g., propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include, but are not limited to, those containing: the compounds provided herein; dialkylated mono- or polyalkylene glycols, including but not limited to 1,2-dimethoxyethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether, tetraethylene glycol dimethyl ether, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, and polyethylene glycol-750-dimethyl ether.Wherein 350, 550, and 750 refer to the approximate average molecular weight of polyethylene glycol; and one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarin, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamates.

[0191] Other formulations include, but are not limited to, aqueous alcohol solutions comprising pharmaceutically acceptable acetals. The alcohols used in these formulations are any pharmaceutically acceptable water-miscible solvent having one or more hydroxyl groups, including, but not limited to, propylene glycol and ethanol. Acetals include, but are not limited to, di(lower alkyl) acetals of lower alkyl aldehydes, such as acetaldehyde diethyl acetal.

[0192] In all embodiments, tablet and capsule formulations may be coated as known to those skilled in the art to alter or maintain the dissolution of the active ingredient. Therefore, for example, they can be coated with conventional enterically digestible coatings such as phenyl salicylate, waxes, and cellulose acetate phthalate.

[0193] B. Injections, Solutions, and Emulsions Parenteral administration is also considered herein, generally characterized by subcutaneous, intramuscular, or intravenous injection. Injections can be prepared in conventional forms, either as liquid solutions or suspensions, suitable as solid forms of solutions or suspensions in liquid prior to injection, or as emulsions. In some embodiments, suspensions are suspensions of microparticles or nanoparticles. In some embodiments, emulsions are emulsions of microparticles or nanoparticles. Suitable excipients are, for example, water, saline, dextran, glycerol, or ethanol. Furthermore, if desired, the pharmaceutical composition to be administered may also contain small amounts of non-toxic excipients such as wetting agents or emulsifiers, pH buffers, stabilizers, solubility enhancers, and other such agents, such as, for example, sodium acetate, sorbitol monolaurate, triethanolamine oleate, and cyclodextrin. Implantation of slow-release or sustained-release systems is also considered herein, such as maintaining a constant dose level. In short, the compounds described herein are dispersed in a solid inner matrix, such as polymethyl methacrylate, polybutyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, silicone carbonate copolymer, hydrophilic polymers such as esters of acrylic acid and methacrylic acid (see specification 73 / 253 pages 94 CN 122003411 A), hydrogels, collagen, crosslinked polyvinyl alcohol, and crosslinked partially hydrolyzed polyvinyl acetate, the solid inner matrix being surrounded by an outer polymer membrane insoluble in body fluids.The outer polymer membrane is made of, for example, polyethylene, polypropylene, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, ethylene / vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, chloroprene rubber, chlorinated polyethylene, polyvinyl chloride, vinyl chloride and vinyl acetate, vinylidene chloride, copolymers of ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubber, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer, and ethylene / vinyloxyethanol copolymer. The compound diffuses across the outer polymer membrane in a release rate control step. The percentage of active compound contained in such parenteral compositions is highly dependent on their specific properties, as well as the activity of the compound and the needs of the subject.

[0194] Parenteral administration of the composition includes intravenous, subcutaneous, and intramuscular administration. Parenteral formulations include sterile solutions ready for injection, sterile dried soluble products such as lyophilized powders (including subcutaneous tablets) ready for use and combined with a solvent just before use, sterile suspensions ready for injection, sterile dried insoluble products ready for use and combined with a solvent just before use, and sterile emulsions. Solutions may be aqueous or non-aqueous.

[0195] If administered intravenously, suitable carriers include physiological saline or phosphate-buffered saline (PBS), and solutions containing thickeners and solubilizers (such as glucose, polyethylene glycol, and polypropylene glycol, and mixtures thereof).

[0196] Pharmaceutically acceptable carriers for parenteral formulations include aqueous solvents, non-aqueous solvents, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifiers, complexing or chelating agents, or other pharmaceutically acceptable substances.

[0197] Examples of aqueous solvents include sodium chloride injection, Ringer's injection, isotonic dextran injection, sterile water injection, and dextran and lactate Ringer's injection. Non-aqueous parenteral solvents include plant-derived fixed oils, cottonseed oil, corn oil, sesame oil, and peanut oil. Antimicrobial agents that inhibit bacteria or fungi must be added to parenteral preparations packaged in multi-dose containers. These antimicrobial agents include phenol or cresol, mercury, benzyl alcohol, chlorobutanol, methylparaben and propylparaben, thimerosal, benzalkonium chloride, and benzyl chloride. Isotonic agents include sodium chloride and dextran. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspensions and dispersants include sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Emulsifiers include polysorbate 80 (TWEEN® 80). Complexing or chelating agents for metal ions include EDTA. Drug carriers also include ethanol, polyethylene glycol, and propylene glycol for water-miscible solvents, and sodium hydroxide, hydrochloric acid, citric acid, or lactic acid for pH adjustment.

[0198] Adjusting the concentration of the pharmaceutically active compound,This allows the injection to provide an effective amount to produce the desired pharmacological effect. The exact dosage depends on the age, weight, and condition of the subject or animal known in the art.

[0199] The unit dose of the parenteral formulation is packaged in ampoules, vials, or syringes with needles. All formulations intended for parenteral administration must be sterile, as is known and practiced in the art.

[0200] Illustratively, intravenous or intra-arterial infusion of a sterile aqueous solution containing the active compound is an effective mode of administration. Another embodiment is a sterile aqueous or oily solution or suspension containing the active substance, which is injected as needed to produce the desired pharmacological effect.

[0201] Injectable formulations are designed for both local and systemic administration. Typically, a therapeutically effective dose is formulated to contain an active compound at a concentration of at least about 0.1% w / w up to about 90% w / w or higher, such as greater than 1% w / w, for the tissue being treated. The active ingredient may be administered once or divided into multiple smaller doses administered at time intervals. It should be understood that the exact dose and duration of treatment are a function of the tissue being treated and can be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It should be noted that concentration and dose values ​​may also vary with the age of the individual receiving treatment. It should be further understood that for any particular subject, the specific dosage regimen should be adjusted over time according to individual needs and the professional judgment of the person administering the formulation (page 74 / 253, 95 CN 122003411 A) or supervising the administration of the formulation, and the concentration ranges listed herein are merely exemplary and not intended to limit the scope or practice of the claimed formulation.

[0202] The compound may be micronized or suspended in other suitable forms, or may be derivatized to produce a more soluble active product or a prodrug. The form of the resulting mixture depends on many factors, including the intended mode of administration and the solubility of the compound in the chosen carrier or solvent. An effective concentration is sufficient to improve the symptoms of the condition and can be determined empirically.

[0203] C. Lyophilized Powders Also of interest herein are lyophilized powders, which can be reconstituted for administration as solutions, emulsions, and other mixtures. They can also be reconstituted and formulated as solids or gels.

[0204] Sterile lyophilized powders are prepared by dissolving the compounds provided herein or their pharmaceutically acceptable salts in a suitable solvent. The solvent may contain excipients that improve the stability of the powder or reconstituted solution prepared from the powder or other pharmacological components. Excipients that may be used include, but are not limited to, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerol, glucose, sucrose or other suitable agents. The solvent may also contain a buffer, such as citrate, sodium phosphate or potassium phosphate or other such buffers known to those skilled in the art, which in one embodiment is approximately neutral pH. The solution is then sterilely filtered and then lyophilized under standard conditions known to those skilled in the art.This provides the desired formulation. Typically, the resulting solution is dispensed into vials for lyophilization. Each vial will contain a single dose (including, but not limited to, 10 to 1000 mg or 100 to 500 mg) or multiple doses of the compound. The lyophilized powder can be stored under suitable conditions, such as at about 4°C to room temperature.

[0205] Reconstitute this lyophilized powder with water for injection to provide a formulation for parenteral administration. For reconstitution, about 1 to 50 mg, about 5 to 35 mg, or about 9 to 30 mg of lyophilized powder is added per mL of sterile water or other suitable carrier. The exact amount depends on the compound selected. Such amounts can be determined empirically.

[0206] D. Topical Application Prepare a surface mixture as described for topical and systemic application. The resulting mixture can be a solution, suspension, emulsion, etc., and can be formulated into creams, gels, ointments, lotions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, rinses, sprays, suppositories, bandages, skin patches, or any other formulation suitable for surface application.

[0207] The compound or a pharmaceutically acceptable salt thereof can be formulated for surface application such as by inhalation as an aerosol (see, for example, U.S. Patents 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivering steroids that can be used to treat inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract can be in the form of an aerosol or a solution for use in a nebulizer, or as a fine powder for blowing in, alone or in combination with an inert carrier such as lactose. In such cases, the particles of the formulation will have a diameter of less than 50 micrometers or less than 10 micrometers.

[0208] The compound can be formulated for topical or surface application, such as for surface application to the skin and mucous membranes, such as in the eyes, in the form of gels, creams and lotions, and for application to the eyes or for intracranial or intraspinal applications. Surface application is considered for percutaneous delivery and also for application to the eyes or mucous membranes, or for inhalation therapy. Nasal solutions of the active compound, alone or in combination with other pharmaceutically acceptable excipients, can also be administered.

[0209] These solutions, especially those intended for ophthalmic use, can be formulated as 0.01% to 10% isotonic solutions with a pH of about 5 to 7, containing suitable salts.

[0210] E. Compositions for Other Routes of Administration Other routes of administration are also covered herein, such as surface application, percutaneous patches and rectal administration.

[0211] For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic action. This document refers to rectal suppositories (pages 75 / 253, 96, CN 122003411 A) as solids for insertion into the rectum that melt or soften at body temperature.This releases one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances for rectal suppositories are bases or solvents and agents that increase the melting point. Examples of bases include cocoa butter (cocoa soybean oil), glycerin gelatin, carbon wax (polyoxyethylene glycol), and suitable mixtures of mono, di, and triglycerides of fatty acids. Various combinations of bases can be used. Agents that increase the melting point of suppositories include cetylene and waxes. Rectal suppositories can be prepared by compression or by molding. An exemplary weight of a rectal suppository is about 2 to 3 grams.

[0212] Tablets and capsules for rectal administration use the same pharmaceutically acceptable substances and are manufactured by the same methods as formulations for oral administration.

[0213] F. Sustained-release compositions The active ingredients provided herein can be administered by controlled-release means or delivery devices well known to those skilled in the art. Examples include, but are not limited to, U.S. Patent Nos. 3,845,770, 3,916,899, 3,536,809, and 3,598,123; and U.S. Patent Nos. 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, 5,639,480, 5,733,566, 5,739,108, 5,891,474, 5,922,356, 5,972,891, 5,980,945, and 5,993,855. Those described in Nos. 6,045,830, 6,087,324, 6,113,943, 6,197,350, 6,248,363, 6,264,970, 6,267,981, 6,376,461, 6,419,961, 6,589,548, 6,613,358, 6,699,500, and 6,740,634, each of which is incorporated herein by reference. Such dosage forms can be used to provide slow or controlled release of one or more active ingredients using, for example, hydroxypropyl methylcellulose, other polymer matrices, gels, permeable membranes, permeation systems, multilayer coatings, microparticles, liposomes, microspheres, or combinations thereof, to provide desired release profiles at varying proportions. Suitable controlled-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients provided herein.

[0214] All controlled-release pharmaceutical products share a common goal: to improve drug therapy.This makes it superior to drug therapies achieved by its uncontrolled counterparts. In one embodiment, the use of an optimized controlled-release formulation in medical treatment is characterized by using the minimum amount of drug substance to cure or control the condition in the minimum amount of time. In some embodiments, the advantages of controlled-release formulations include prolonged drug activity, reduced dosing frequency, and increased subject compliance. Furthermore, controlled-release formulations can be used to influence the time of onset of action or other characteristics, such as blood levels of the drug, and thus can influence the occurrence of side effects (e.g., adverse reactions).

[0215] Most controlled-release formulations are designed to initially release a certain amount of drug (active ingredient), which rapidly produces the desired therapeutic effect, and to gradually and continuously release additional amounts of drug to maintain that level of therapeutic or preventative effect over a prolonged period of time. In order to maintain such a constant level of drug in the body, the drug must be released from the dosage form at a rate that replaces the amount of drug metabolized and excreted from the body. The controlled release of the active ingredient can be stimulated by a variety of conditions, including but not limited to pH, temperature, enzymes, water, or other physiological conditions or compounds.

[0216] In some embodiments, the agent may be administered via intravenous infusion, implantable osmotic pump, transdermal patch, liposome or other administration methods. In one embodiment, a pump may be used (see, Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989). In another embodiment, a polymeric material may be used. In yet another embodiment, the controlled release system may be placed near the therapeutic target, i.e., thus requiring only a portion of the systemic dose (see, for example, Goodson, Medical Applications of Controlled Release, Vol. 2, pp. 115-138 (1984). Specification 76 / 253 pages 97 CN 122003411 A

[0217] In some embodiments, the controlled release device is introduced into the subject at inappropriate sites of immune activation or near tumors. Langer discusses other controlled release systems in a review (Science 249:1527-1533). (1990). Active ingredients can be dispersed in a solid matrix.Examples include polymethyl methacrylate, polybutyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, and polyisobutylene. The parenteral matrix consists of polybutadiene, polyethylene, ethylene-vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, silicone carbonate copolymer, hydrophilic polymers such as esters of acrylic acid and methacrylic acid, hydrogels, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate. This solid inner matrix is ​​surrounded by an outer polymer membrane insoluble in body fluids, such as polyethylene, polypropylene, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, ethylene / vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, chloroprene rubber, chlorinated polyethylene, polyvinyl chloride, vinyl chloride and vinyl acetate, vinylidene chloride, copolymers of ethylene and propylene, ionic polymers such as polyethylene terephthalate, butyl rubber, epichlorohydrin rubber, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer, and ethylene / vinyloxyethanol copolymer. The active ingredient then diffuses across the outer polymer membrane in a release rate-controlled step. The percentage of active ingredient contained in such parenteral compositions is highly dependent on their specific properties and the needs of the subject.

[0218] G. Targeting Formulations The compounds provided herein or their pharmaceutically acceptable salts may also be formulated to target specific tissues, receptors, or other regions of the body of a subject to be treated, including liposome-based, resealed red blood cell, and antibody-based delivery systems. Many such targeting methods are well known to those skilled in the art. All such targeting methods are contemplated herein for use in this composition. For non-limiting examples of targeting methods, see, for example, U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542, and 5,709,874.

[0219] In one embodiment, the antibody-based delivery system is an antibody-drug conjugate (“ADC”), for example,For example, Hamilton GS, Biologicals, Sep 2015, 43(5):318-32; Kim EG and Kim KM, Biomol. Ther. (Seoul), Nov 2015, 23(6):493-509; and Peters C and Brown S, Biosci. Rep., 12 June 2015, 35(4) pii: e00225, each incorporated herein by reference.

[0220] In one embodiment, liposome suspensions, including tissue-targeting liposomes, such as tumor-targeting liposomes, may also be suitable as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art. For example, liposome formulations can be prepared as described in U.S. Patent No. 4,522,811. In short, liposomes such as multilayer vesicles (MLVs) can be formed by drying the inside of a flask with lecithin choline and cephalin acylserine (7:3 molar ratio). A solution of the compound provided herein in phosphate-buffered saline (PBS) lacking divalent cations is added, and the flask is shaken until the lipid membrane disperses. The resulting vesicles are washed to remove unencapsulated compounds, granulated by centrifugation, and then resuspended in PBS.

[0221] H. Articles of manufacture: The compound or pharmaceutically acceptable salt may be packaged as an article containing packaging material for the treatment, prevention, or improvement of one or more symptoms or progressions of the disease or condition disclosed herein, and a label indicating that the compound or pharmaceutically acceptable salt thereof is used for the treatment, prevention, or improvement of one or more symptoms or progressions of the disease or condition disclosed herein, and a label indicating that the compound or pharmaceutically acceptable salt thereof is used for the treatment, prevention, or improvement of one or more symptoms or progressions of the disease or condition disclosed herein.

[0222] Articles of manufacture provided herein contain packaging material. Packaging materials used for packaging pharmaceutical products are well known to those skilled in the art (page 77 / 253, CN 122003411 A). See, for example, U.S. Patent Nos. 5,323,907, 5,052,558, and 5,033,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, pens, bottles, and any packaging material suitable for the selected formulation and intended administration and treatment modality. Consider various formulations of the compounds and compositions provided herein.

[0223] In some embodiments, a kit is also provided herein that, when used by a healthcare professional, simplifies the administration of an appropriate amount of the active ingredient to a subject. In some embodiments, the kit provided herein includes a container and a dosage form of the compound provided herein.The compound includes a single enantiomer or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0224] In some embodiments, the kit includes a container containing a dosage form of the compound provided herein, in a container containing one or more other therapeutic agents described herein, the compound including a single enantiomer or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0225] The kits provided herein may further include a device for administering the active ingredient. Examples of such devices include, but are not limited to, syringes, needle-free injector drop bags, patches, and inhalers. The kits provided herein may also include a condom for administering the active ingredient.

[0226] The kits provided herein may further include a pharmaceutically acceptable solvent that can be used to administer one or more active ingredients. For example, if the active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit may contain a sealed container of a suitable solvent in which the active ingredient can be dissolved to form a particulate-free sterile solution suitable for parenteral administration. Examples of pharmaceutically acceptable solvents include, but are not limited to: aqueous solvents, including but not limited to USP water for injection, sodium chloride injection, Ringer's solution injection, dextran injection, dextran and sodium chloride injection, and lactate Ringer's solution injection; water-miscible solvents, including but not limited to ethanol, polyethylene glycol, and polypropylene glycol; and non-aqueous solvents, including but not limited to corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[0227] V. Administration The compounds and pharmaceutical compositions provided herein may be administered in certain therapeutic or prophylactic effective amounts, at certain time intervals, in certain dosage forms, and in certain methods of dosing as described below.

[0228] In some embodiments, the therapeutic or preventative effective amount of the compound is about 0.005 to about 1,000 mg per day, about 0.01 to about 500 mg per day, about 0.01 to about 250 mg per day, about 0.01 to about 100 mg per day, about 0.1 to about 100 mg per day, about 0.5 to about 100 mg per day, about 1 to about 100 mg per day, about 0.01 to about 50 mg per day, about 0.1 to about 50 mg per day, about 0.5 to about 50 mg per day, about 1 to about 50 mg per day, about 0.02 to about 25 mg per day, about 0.05 to about 10 mg per day, about 0.05 to about 5 mg per day, about 0.1 to about 5 mg per day, or about 0.5 to about 5 mg per day.

[0229] In some embodiments,The effective dose for treatment or prevention is about 0.1 mg, about 0.2 mg, about 0.5 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 45 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, or about 150 mg daily.

[0230] In one embodiment, for the condition described herein, the recommended daily dose range of the compound or its derivative provided herein is from about 0.5 mg to about 50 mg daily, given as a single dose once daily in one embodiment, or in divided doses throughout the day. In some embodiments, the dose range is from about 1 mg to about 50 mg daily. In other embodiments, the dose range is from about 0.5 mg to about 5 mg daily. The specific daily dosage includes 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, or 50 mg daily. (Instructions for use, pages 78 / 253, 99 CN 122003411 A)

[0231] In a specific embodiment, the recommended starting dose may be 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, or 50 mg daily. In another embodiment, the recommended starting dose may be 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg daily. The dose may be increased to 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, and 50 mg daily. In a specific embodiment, the compound may be administered at a dose of about 25 mg / day. In a specific embodiment,The compound can be administered at a dose of about 10 mg / day. In a specific embodiment, the compound can be administered at a dose of about 5 mg / day. In a specific embodiment, the compound can be administered at a dose of about 4 mg / day. In a specific embodiment, the compound can be administered at a dose of about 3 mg / day.

[0232] In some embodiments, the effective dose for treatment or prevention is about 0.001 to about 100 mg / kg / day, about 0.01 to about 50 mg / kg / day, about 0.01 to about 25 mg / kg / day, about 0.01 to about 10 mg / kg / day, about 0.01 to about 9 mg / kg / day, 0.01 to about 8 mg / kg / day, about 0.01 to about 7 mg / kg / day, about 0.01 to about 6 mg / kg / day, about 0.01 to about 5 mg / kg / day, about 0.01 to about 4 mg / kg / day, about 0.01 to about 3 mg / kg / day, about 0.01 to about 2 mg / kg / day, about 0.01 to about 1 mg / kg / day, or about 0.01 to about 0.05 mg / kg / day.

[0233] The dosage may also be expressed in units other than mg / kg / day. For example, a dose for parenteral administration may be expressed as mg / m² / day. Those skilled in the art will readily know how to convert the dose from mg / kg / day to mg / m² / day based on the height or weight of a given subject or both (see www.fda.gov / cder / cancer / animalframe.htm). For example, a dose of 1 mg / kg / day for a 65 kg person is approximately equal to 38 mg / m² / day.

[0234] In some embodiments, the amount of compound administered is sufficient to provide a steady-state plasma concentration of the compound, ranging from about 0.001 to about 500 µM, about 0.002 to about 200 µM, about 0.005 to about 100 µM, about 0.01 to about 50 µM, about 1 to about 50 µM, about 0.02 to about 25 µM, about 0.05 to about 20 µM, about 0.1 to about 20 µM, about 0.5 to about 20 µM, or about 1 to about 20 µM.

[0235] In other embodiments, the amount of compound applied is sufficient to provide a steady-state plasma concentration of the compound, ranging from about 5 to about 100 nM, about 5 to about 50 nM, about 10 to about 100 nM, about 10 to about 50 nM, or about 50 to about 100 nM.

[0236] As used herein,The term "steady-state plasma concentration" is the concentration reached after a period of time following administration of the compound or its derivatives provided herein. Once steady state is reached, small peaks and troughs are present on the time-dependent curve of the plasma concentration of the compound.

[0237] In some embodiments, the amount of the compound administered is sufficient to provide the maximum plasma concentration (peak concentration) of the compound, ranging from about 0.001 to about 50 µM, about 0.002 to about 200 µM, about 0.005 to about 100 µM, about 0.01 to about 50 µM, about 1 to about 50 µM, about 0.02 to about 25 µM, about 0.05 to about 20 µM, about 0.1 to about 20 µM, about 0.5 to about 20 µM, or about 1 to about 20 µM.

[0238] In some embodiments, the amount of compound applied is sufficient to provide a minimum plasma concentration (trough concentration) of the compound, ranging from about 0.001 to about 500 µM, about 0.002 to about 200 µM, about 0.005 to about 100 µM, about 0.01 to about 50 µM, about 1 to about 50 µM, about 0.01 to about 25 µM, about 0.01 to about 20 µM, about 0.02 to about 20 µM, about 0.02 to about 20 µM, or about 0.01 to about 20 µM. Specification 79 / 253 pages 100 CN 122003411 A

[0239] In some embodiments, the amount of compound applied is sufficient to provide the area under the curve (AUC) of the compound, ranging from about 100 to about 100,000 ng hr / mL, about 1,000 to about 50,000 ng hr / mL, about 5,000 to about 25,000 ng hr / mL, or about 5,000 to about 10,000 ng hr / mL.

[0240] The methods provided herein include treating patients regardless of the age of the subject, although some diseases or conditions are more common in certain age groups.

[0241] Depending on the disease to be treated and the condition of the subject, the compounds or derivatives thereof provided herein may be administered via oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, CIV, intracisional injection or infusion, subcutaneous injection or implantation), inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., percutaneous or local) routes of administration. The compounds or derivatives thereof provided herein may be formulated alone or together with pharmaceutically acceptable excipients, carriers, adjuvants, and solvents in appropriate dosage units to suit each route of administration.

[0242] In one embodiment, the compounds or derivatives thereof provided herein are administered orally. In another embodiment,The compounds or derivatives thereof provided herein are administered parenterally. In yet another embodiment, the compounds or derivatives thereof provided herein are administered intravenously.

[0243] The compounds or derivatives thereof provided herein may be delivered as a single dose, such as, for example, a single large injection or oral tablet or pill; or delivered over time, such as, for example, continuous infusion over time or fractional large doses over time. If necessary, the compounds may be repeated, for example, until the subject experiences disease stabilization or regression, or until the subject experiences disease progression or unacceptable toxicity. For example, disease stabilization in solid tumors generally means that the vertical diameter of the measurable lesion has not increased by 25% or more compared to the last measurement. Solid Tumor Response Evaluation Criteria (RECIST) Guidelines, Journal of the National Cancer Institute 92(3): 205 216 (2000). Disease stabilization or the absence of disease stabilization is determined by methods known in the art, such as assessment of patient symptoms; physical examination; visualization of the tumor that has been imaged using X-ray, CAT, PET or MRI scans; and other generally accepted assessment methods.

[0244] The compounds or derivatives thereof provided herein may be administered once daily (QD) or divided into multiple daily doses, such as twice daily (BID), three times daily (TID), and four times daily (QID). Furthermore, administration may be continuous (i.e., for several consecutive days each day, or every single day), intermittent, such as cyclical administration (i.e., including drug-free rest periods of several days, weeks, or months). As used herein, the term “daily” means a therapeutic compound, such as the compounds or derivatives thereof provided herein, administered once or more daily, for example, for a period of time. The term “continuous” means daily administration of a therapeutic compound, such as the compounds or derivatives thereof provided herein, for an uninterrupted period of at least 10 days to 52 weeks. As used herein, the terms “intermittent” or “intermittently” mean stopping and starting at regular or irregular intervals. For example, intermittent administration of the compounds or derivatives thereof provided herein may be administered one to six days per week, cyclical administration (e.g., daily administration for two to eight consecutive weeks, followed by a rest period of up to one week without administration), or administration every other day. As used herein, the term "cycle" means daily or continuous administration of a therapeutic compound, such as those provided herein or their derivatives, but with rest periods. In some such embodiments, administration is once daily for two to six days, followed by a rest period in which no administration is performed for five to seven days.

[0245] In some embodiments, the frequency of administration ranges from about a daily dose to about a monthly dose. In some embodiments, administration is once daily, twice daily, three times daily, four times daily, every other day, twice weekly, once weekly, once every two weeks, once every three weeks, or once every four weeks. In one embodiment,The compounds or derivatives thereof provided herein are administered once daily. In another embodiment, the compounds or derivatives thereof provided herein are administered twice daily. In another embodiment, the compounds or derivatives thereof provided herein are administered three times daily. In another embodiment, the compounds or derivatives thereof provided herein are administered four times daily.

[0246] In some embodiments, the compounds or derivatives thereof provided herein are administered once daily for one to six months, one week to three months, one week to four weeks, one week to three weeks, or one week to two weeks. In some embodiments, the compounds or derivatives thereof provided herein are administered once daily for one week, two weeks, three weeks, or four weeks. In one embodiment, the compounds or derivatives thereof provided herein are administered once daily for four days. In one embodiment, the compounds or derivatives thereof provided herein are administered once daily for five days. In one embodiment, the compounds or derivatives thereof provided herein are administered once daily for six days. In one embodiment, the compounds or derivatives thereof provided herein are administered once daily for one week. In another embodiment, the compounds or derivatives thereof provided herein are administered once daily for two weeks. In another embodiment, the compounds or derivatives thereof provided herein are administered once daily for three weeks. In another embodiment, the compounds or derivatives thereof provided herein are administered once daily for four weeks.

[0247] VI. Treatment Methods Inhibitors of KAT-mediated post-translational lysine acetylation of the MYST family are promising antitumor agents and are therefore useful therapeutic agents, for example, for the treatment of cancer. Such agents can also be used as therapeutic agents for cancers exhibiting overexpression of MYST proteins.

[0248] In another embodiment, a method is provided for treating a subject with cancer by administering a compound or composition provided herein. In another embodiment, a method is provided herein for treating a condition, disease, or symptom by inhibiting the MYST family of lysine acetyltransferases (including KAT6A and KAT6B), the method comprising administering a therapeutically effective amount of a compound or composition provided herein.

[0249] In another embodiment, a method is provided for treating a condition, disease, or symptom where the condition, disease, or symptom is a hyperproliferative disease, such as cancer. In some embodiments, the cancer is selected from: lymphoma, melanoma, carcinomas (e.g., adenocarcinoma, hepatocellular carcinoma, medullary carcinoma, papillary carcinoma, squamous cell carcinoma), astrocytoma, glioma, medulloblastoma, myeloma, meningioma, neuroblastoma, and sarcoma (e.g., angiosarcoma, chondrosarcoma, osteosarcoma). In some embodiments, the cancer is a cancer that overexpresses MYST. In another embodiment, the cancer overexpresses the MYST protein relative to non-cancerous tissue. In some embodiments,Cancer, compared to non-cancerous tissue, overproduces MYST mRNA. In another embodiment, the cancer is a cancer that overexpresses MYST, wherein the overexpressed MYST protein or MYST mRNA is any of the KAT family members of the MYST family, such as KAT6A. In some embodiments, the cancer is leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), non-Hodgkin's lymphoma, Hodgkin's disease, prostate cancer, lung cancer, melanoma, breast cancer, ductal carcinoma of the breast, colorectal cancer, colon cancer, squamous cell carcinoma, gastric cancer, adrenocortical carcinoma, anal cancer, bladder cancer, blood cancer, bone cancer, brain tumor, female reproductive system cancer, male reproductive system cancer (including testicular cancer and penile cancer), central nervous system lymphoma, cervical cancer, rhabdomyosarcoma in children, sarcoma in children, endometrial cancer, endometrial sarcoma, esophageal cancer, eye cancer, gallbladder cancer, gastrointestinal cancer, etc. Hairy cell leukemia, head and neck cancer, hepatocellular carcinoma, hypopharyngeal cancer, Kaposi's sarcoma, kidney cancer, laryngeal cancer, liver cancer, malignant fibrous histiocytoma, malignant thymoma, mesothelioma, multiple myeloma, myeloma, nasal cavity and paranasal sinus cancer, nasopharyngeal carcinoma, nervous system cancers, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, pharyngeal cancer, pituitary adenoma, plasma cell neoplasm, primary CNS lymphoma, rectal cancer, respiratory system cancer, retinoblastoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, gastric cancer, testicular cancer, thyroid cancer, urinary system cancer, uterine cancer, uterine sarcoma, vaginal cancer, endocrine cancer, central nervous system (CNS) neoplasm, primary CNS lymphoma, spinal axis tumor, glioblastoma, brainstem glioma, pituitary adenoma, vascular system cancer, Waldenström macroglobulinemia, or Wilms' tumor. In some embodiments, the cancer is breast cancer, including ER-positive breast cancer, non-small cell lung cancer, prostate cancer, pancreatic cancer, ovarian cancer, or blood cancer (including leukemia or lymphoma). In one embodiment, the cancer is breast cancer, lung cancer, ovarian cancer, colon cancer, prostate cancer, uterine / cervical cancer, or leukemia. Specification 81 / 253 pages 102 CN 122003411 A

[0250] In another embodiment, a method is provided to inhibit the activity of MYST KAT by contacting MYST KAT or a composition containing MYST KAT with a compound or composition provided herein. In one embodiment, MYST KAT is KAT6 lysine acetyltransferase. In another embodiment, MYST KAT is KAT6A.

[0251] Not wishing to be bound by any theory,One aspect of the catalytic mechanism of the KAT family of enzymes is the acetylation of lysine residues using the cofactor Ac-CoA as an acetyl donor. One possible catalytic mechanism is the stepwise transfer of the acetyl group from acetyl-CoA (Ac-CoA) to transiently form an acetyl-enzyme intermediate. This acetyl-enzyme intermediate is then the source of the acetyl group transferred to the substrate, which is typically a lysine residue on a histone (Wapenaar et al., 2016, ibid.). In the MYST family of KAT, a conserved cysteine ​​residue is transiently acylated as part of the catalytic cycle, as shown in bold C in the sequence below.

[0252] Amino acid sequence alignment near the Ac-CoA binding site of the MYST family of KAT Therefore, in one embodiment, a method is provided to inhibit MYST KAT by covalently modifying this conserved cysteine ​​residue with a compound or composition provided herein. In another embodiment, a method is provided to covalently modify the conserved MYST KAT cysteine ​​residue by contacting MYST KAT or a composition containing MYST KAT with a compound or composition provided herein.

[0253] In another embodiment, histone acetyltransferases or HATs, including KAT6, are known in the art to play a key role in promoting myc-driven transcriptional regulation. Myc is a transcriptional regulator known to recruit HATs to target chromatin, thereby promoting chromatin remodeling, leading to transcription, proliferation, and tumor growth. Myc is a transcriptional regulator that has many protein-protein interacting factors in a series of complexes mediating this transcriptional activity. One such interacting protein, called a transformation / transcription domain-associated protein or TRRAP, is a member of several HAT-containing protein complexes in which it acts as a bridging protein between transcription factors such as myc and HAT. Myc has been shown to recruit histone acetylation via the TRRAP complex, thereby promoting nucleosome acetylation at histone H4 via HATs, including but not limited to KAT2A and KAT5, as well as Tip60 / p400. This myc-associated HAT activity enables chromatin structural development, thereby promoting transcription (see, for example, Laurenco et al., Nature Reviews Cancer 2021, 21, 579-591). Myc recruits HATs to target chromatin and locally promotes the acetylation of multiple specific lysines on both H3 and H4, some of which are known targets of KAT6A acetylation, leading to transcriptional activation (see, for example, Martinato et al.).PL o SONE 2008, 3 (11), e3650, doi: 10.1371 / journal.pone.0003650). KAT6A, as a recruitable HAT, plays a role in specific cancers and cell types and may be a key mediator of HAT activity recruited to myc-driven transcriptional activation sites in some tumors.

[0254] Furthermore, by using KAT6A inhibitors, the hallmark targets of myc-induced transcriptional regulation (myc pathway targets) are reduced. This includes the myc pathway in breast cancer cell lines where KAT6A is amplified after administration of a KAT6 inhibitor (see specification 82 / 253, page 103, CN 122003411 A, e.g., Sharma et al., Cell Chemical Biology 2023, doi.org / 10.1016 / j.chembiol.2023.07.005).

[0255] Indeed, there is direct evidence that KAT6 may be a key HAT in myc-driven transcriptional regulation, and that loss of KAT6 activity may disrupt myc-driven transcriptional programming. Systemic administration of a KAT6 inhibitor inhibited Myc-driven growth in lymphoma cell lines. Specifically, two small molecule inhibitors of KAT6A and KAT6B elicited antitumor activity in MYC-driven lymphoma models (see, for example, Baell et al., Nature 2018, 560, 253–257; Priebbenow et al., J. Med. Chem. 2020, 63, 4655–4684). Finally, MYC is amplified in approximately 30% of solid tumors, including lung cancer, ovarian cancer, esophageal cancer, breast cancer, gastric cancer, pancreatic cancer, and liver cancer. There are many overlapping solid tumor types that have characteristic myc activity and also contain KAT6 genome amplification. Therefore, inhibition of KAT6A activity is expected to reduce transcriptional activity and tumorigenicity in solid tumors where myc is a key transcriptional regulator.

[0256] Therefore, in another embodiment, a method of treating a subject with myc-driven cancer by administering the compounds or compositions provided herein to a subject is provided. In another embodiment, the myc-driven cancer is lung cancer, ovarian cancer, esophageal cancer, breast cancer, stomach cancer, pancreatic cancer, or liver cancer. In another embodiment, the myc-driven cancer is a cancer in which myc is amplified. In another embodiment,A method is provided for treating a subject with cancer in which myc is amplified by administering a compound or composition provided herein to the subject.

[0257] KAT6A is an acetyltransferase of p53 at K120 and K382 and colocalizes with p53 in the nucleosome of promyelocytic leukemia (PML) after cellular stress (Rokudai et al. PNAS 2013, 110(10), 3895-3900). This ternary complex enhances p53-dependent p21 expression. Therefore, KAT6A acetylation of p53, which affects the formation or stability of the complex and alters its downstream activity, is involved in the pathogenesis of tumors and leukemia. Therefore, KAT6A inhibitors can be used to treat hematologic cancers. Therefore, in another embodiment, a method is provided for treating a subject with hematologic cancers by administering a compound or composition provided herein to the subject.

[0258] KAT6A acetylation of SMAD3 regulates bone marrow-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer (Yu et al. Adv. Sci. 2021, 8, 2100014). Therefore, KAT6A inhibitors can be used to treat TNBC. In another embodiment, a method is provided to treat a subject with TNBC by administering the compounds or compositions provided herein to a subject.

[0259] VII. Combination therapy with other active agents The compounds provided herein or derivatives thereof may also be used in combination with other therapeutic agents that can be used to treat and / or prevent hyperproliferative diseases, including cancer.

[0260] In one embodiment, a method is provided herein for treating, preventing, or managing hyperproliferative diseases, including cancer, comprising administering to a subject the compounds provided herein or derivatives thereof; in combination with one or more second active agents.

[0261] As used herein, the term “combination” includes the use of more than one therapy (e.g., one or more preventive and / or therapeutic agents). However, the use of the term "combination" does not limit the order in which therapies (e.g., preventative and / or therapeutic agents) are administered to a subject with a disease or condition. The first therapy (e.g., a preventative or therapeutic agent, such as the compounds or derivatives thereof provided herein) may be administered to the subject before (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) the second therapy (e.g., a preventative or therapeutic agent).Administration at 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks. Triple therapy is also considered herein.

[0262] Administration of the compound or derivative thereof provided herein and one or more other active agents to a subject may occur simultaneously or sequentially via the same or different routes of administration. The suitability of a particular route of administration for a particular active agent will depend on the active agent itself (e.g., whether it can be administered orally before entering the bloodstream without dissolving) and the disease or condition being treated.

[0263] The route of administration of the compound or derivative thereof provided herein is independent of the route of administration of a second therapy. In one embodiment, the compound or derivative thereof provided herein is administered orally. In another embodiment, the compound or derivative thereof provided herein is administered intravenously. Therefore, according to these embodiments, the compounds or derivatives thereof provided herein are administered orally or intravenously, and the second therapy may be administered orally, parenterally, intraperitoneally, intravenously, intra-arterially, percutaneously, sublingually, intramuscularly, rectally, orally, intranasally, via liposomes, via inhalation, vaginally, intraocularly, via catheter or stent local delivery, subcutaneously, intra-articularly, intrathecally, or in a slow-release formulation. In one embodiment, the compounds or derivatives thereof provided herein and the second therapy are administered via the same administration modality, orally or via IV. In another embodiment, the compounds or derivatives thereof provided herein are administered via one administration modality (e.g., via IV), while the second agent is administered via another administration modality (e.g., orally).

[0264] In one embodiment, the second active agent is administered intravenously or subcutaneously in amounts of about 1 to about 1000 mg, about 5 to about 500 mg, about 10 to about 350 mg, or about 50 to about 200 mg once or twice daily. The specific amount of the second active agent will depend on the particular pharmaceutical agent used, the type of disease being treated or managed, the severity and stage of the disease, and the amount of the compound or its derivatives provided herein and any optional additional active agents administered concurrently to the subject.

[0265] One or more other active ingredients or pharmaceutical agents may be used together with the compound or its derivatives provided herein in the methods and compositions provided herein. Other active agents may be macromolecules (e.g., proteins) or small molecules (e.g., synthetic inorganic, organometallic, or organic molecules).

[0266] Examples of macromolecular active agents include, but are not limited to, hematopoietic growth factors, cytokines, and monoclonal and polyclonal antibodies, which are immune-based therapeutic agents in a classification known as immuno-oncology.Improving immune-mediated recognition of tumors, particularly therapeutic antibodies against cancer antigens. Typical macromolecular active agents are biomolecules, such as naturally occurring proteins or synthetic or recombinant proteins.

[0267] In one embodiment, the compound or derivative thereof provided herein is administered orally and daily in amounts of about 0.1 to about 150 mg, about 1 to about 25 mg, or about 2 to about 10 mg, either alone or in combination with a second active agent before, during, or after conventional therapy.

[0268] In another embodiment, the choice of other active agents depends on the disease to be treated. Examples of second active agents for specific cancers are well known to those skilled in the art. For example, if the disease is breast cancer, the second active agent may be an aromatase inhibitor, a CDK4 / 6 inhibitor, or an ER antagonist. Other examples of agents that can be combined with a KAT6 inhibitor for the treatment of breast cancer are selective inhibitors of cyclin-dependent kinases such as CDK2 or CDK4 inhibitors and selective estrogen receptor degraders (SERDs). PIK3CA is a common mutant oncogene in breast cancer. The H1047R mutation of PIK3CA is very common in breast cancer and other solid tumors. KAT6 inhibitors can be combined with mutant-selective PI3Kα inhibitors for the treatment of breast cancer and other cancers.

[0269] Another example of a type of solid tumor carrying the KAT6A genome and mRNA amplification is ovarian cancer. Ovarian cancer is treated with platinum-based chemotherapy such as cisplatin, which has high levels of toxicity, which often limits the dosing instructions 84 / 253 pages 105 CN 122003411 A and the achievement of maximum effective exposure. In some cases, PARP inhibitors or CDK2 inhibitors are used to treat ovarian cancer. KAT6 inhibitors can be used in combination with these agents for the treatment of ovarian cancer, but are not limited to these agents.

[0270] KAT6 epigenetic activity has been shown to be involved in the development of resistance to menin pathway inhibitors and has been shown to play a role in chromatin remodeling in solid tumors as well as AML via the menin-MLL / KMT2 complex. KAT6 inhibitors and menin pathway inhibitors can be used to treat hematologic cancers such as AML and tumors, where the menin-MLL / KMT2 complex, alone or in combination with menin, drives tumor growth.

[0271] VIII. Examples The following examples are intended to illustrate certain embodiments provided herein and not to limit the scope of this disclosure.

[0272] As used herein, the symbols and conventions used in these processes, procedures, and examples, whether or not specific abbreviations are specifically defined, are consistent with the symbols and conventions used in contemporary scientific literature.For example, Journal of the American Chemical Society or Journal of Biological Chemistry. Specifically, but not limited to, the following abbreviations may be used in examples and throughout the instruction manual: g (gram); mg (milligram); mL (milliliter); μL (microliter); mM (millimolecular concentration); μM (micromolar concentration); Hz (hertz); MHz (megahertz); mmol (millimole); h, hr, or hrs (hour); min (minute); MS (mass spectrometry); ESI (electrospray ionization); rt (room temperature); Rf (retention factor); TLC (thin-layer chromatography); LCMS (liquid chromatography-mass spectrometry); HPLC (high-performance liquid chromatography); AcOH (acetic acid); n-BuLi (n-butyllithium); tBuOK (potassium tert-butoxide); CDCl3 (chloroform-d); CH3CN (acetonitrile); Cs2CO3 (cesium carbonate); DMF (N,N-dimethylformamide); DCM (dichloromethane); DEA (diethylamine); DIPEA (diisopropylethylamine); DMSO (dimethyl sulfoxide); DMSO-d6 (dimethyl sulfoxide-d6); EtOAc Or EA (ethyl acetate); Et3N (triethylamine); EtOH (ethanol); HCl (hydrochloric acid); H2SO4 (sulfuric acid); K2CO3 (potassium carbonate); LiOH (lithium hydroxide); MsCl (methanesulfonyl chloride); MeI (iodomethane); MeOH (methanol); MeOH-d4 (methanol-d4); NaBH4 (sodium borohydride); NaH (sodium hydride); NaHCO3 (sodium bicarbonate); NaNO2 (sodium nitrite); NaOH (sodium hydroxide); NaOMe (sodium methoxide); Na2SO4 (sodium sulfate); K3FeCN6 (potassium ferrohydride); Pd(PPh3)4 (tetra(triphenylphosphine)palladium(O)); SO2 (sulfur dioxide); SO2Cl2 (thioyl chloride); T3P (propanephosphonic anhydride); THF (tetrahydrofuran); TMEDA (1,2-bis(dimethylamino)ethane); Zn (zinc); ZnCN2 (zinc cyanide).

[0273] For all the following examples, standard post-processing and purification methods known to those skilled in the art can be utilized. Unless otherwise stated, all temperatures are expressed in °C (degrees Celsius). Unless otherwise stated, all reactions are carried out at room temperature. The synthetic methods illustrated herein are intended to illustrate applicable chemistry through the use of specific examples.And does not indicate the scope of this disclosure.

[0274] Examples 1 to 2 Scheme 1: Synthesis of 5-chloro-2-methoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthesis Example 1) and 5-chloro-2-methoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthesis Example 2) Specification 85 / 253 pages 106 CN 122003411 A Synthesis of 4-bromo-2-fluoro-6-methoxybenzonitrile (2) Compound 1 (50 g, 229.35 mmol) was subjected to MeOH (500 NaOMe (14.86 g, 275.22 mmol) was added to the stirred solution in methanol (140 mL) and the reaction mixture was stirred at 0 °C for 2 h. After completion (monitored by TLC), the mixture was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give title compound 2 (55 g) as a yellow solid. LCMS: C8H5BrFNO calculated value: 228.95; measured value: 229.5 (M+1).

[0275] Synthesis of methyl 4-cyano-3-fluoro-5-methoxybenzoate (3) Triethylamine (1.58 mL, 11.303 mmol) was added to the solution of compound 2 (13 g, 56.511 mmol) in methanol (140 mL) in a steel reactor and purged with nitrogen for 5 min. Palladium(II) acetate (634 mg, 2.823 mmol) and DPPP (1,3-bis(diphenylphosphine)propane) (2.33 g, 5.59 mmol) were added, and the reaction mixture was heated at 80 °C for 16 h in the presence of CO gas (110 psi). After completion (monitored by TLC),The mixture was cooled to room temperature and filtered through a diatomaceous earth bed. The filtrate was concentrated under vacuum and purified by combi-flash chromatography using 14% EtOAc / hexane to give methyl 4-cyano-3-fluoro-5-methoxybenzoate 3 (10 g, 47.81%) as a white solid. TLC: 20% EtOAc / heptane (Rf: 0.5). LCMS: Calculated value of C10H8FNO3: 209.05; Found value: 210.0 (M+1).

[0276] Synthesis of 2-fluoro-4-(hydroxymethyl)-6-methoxybenzonitrile (4) Compound 3 (10 g, 47.80 mmol) was added dropwise to a stirred solution of LiBH4 (2.08 g, 95.611 mmol) in THF (100 mL) in THF (600 mL) at 0 °C. The reaction mixture was stirred at 80 °C for 4 h. After completion (monitored by TLC), the mixture was cooled to RT, quenched with ice-cold water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to give title compound 4 (6 g, 69.27%) as a white solid. TLC: 50% EtOAc / heptane (Rf: 0.25). LCMS: Calculated value of C₁₈FNO₂: 181.05; Found value: 182.0 (M+1).

[0277] Synthesis of 4-(bromomethyl)-2-fluoro-6-methoxybenzonitrile (5) PPh3 (16.82 g, 64.138 mmol) was added to a stirred solution of compound 4 (7 g, 38.637 mmol) in ACN (70 mL), followed by the addition of Br2 (3.08 mL, 64.137 mmol) at 0 °C. The reaction mixture was stirred at 60 °C for 2 hours. After completion (monitored by TLC), the mixture was quenched with sodium thiosulfate (110 mL) and extracted with EtOAc (3 x 60 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under vacuum. The crude product was purified by combi-flash chromatography (15% EtOAc in heptane).To obtain title compound 5 as a white solid (4 g, 16.389 mmol, 42.46%). TLC: 30% EtOAc / heptane (Rf: 0.6). LCMS: C9H7BrFNO. Calculated value: 242.97; Found value: 244.2 (M+2), from CN 122003411 A, page 86 / 253 of the specification.

[0278] Synthesis of tert-butyl 2-(4-cyano-3-fluoro-5-methoxybenzyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate and tert-butyl 2-(4-cyano-3-fluoro-5-methoxybenzyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (6): DIPEA (2.146 mL, 12.292 mmol) was added to a stirred solution of compound 5 (1.0 g, 4.097 mmol) in acetonitrile (5 mL), followed by the addition of tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (1.02 g, 4.916 mmol). The reaction mixture was heated at 70 °C for 6 h. After completion (monitored by TLC), the reaction mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using a gradient method of 0-50% EtOAc / heptane to give title compound 6 as a yellow solid (1.0 g, 48.65%, separated as an inseparable mixture of regioisomers). TLC: 80% EtOAc / heptane (Rf: 0.45). LCMS: Calculated value of C₁₉H₂₁FN₄O₃: 372.16; Found value: 373.40 (M+1).

[0279] Synthesis of tert-butyl 1-((3-amino-4-methoxybenzo[d]isoxazol-6-yl)methyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate and tert-butyl 2-((3-amino-4-methoxybenzo[d]isoxazol-6-yl)methyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (7): Acetyloxyoxime acid (0.31 g, 4.02 mmol) was added to a stirred solution of compound 6 (a mixture of regioisomers) (0.50 g, 1.34 mmol) in DMF (7 mL), followed by the addition of K2CO3 (0.56 g, 4.02 mmol). The reaction mixture was stirred at 65 °C for 16 h. After completion (monitored by TLC), the mixture was cooled to room temperature and quenched with ice water. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine.The sample was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by silica gel (100-200 mesh) column chromatography using a gradient method of 0-50% EtOAc / heptane to give title compound 7 as a grayish-white solid (0.20 g, 38.64%, separated as an inseparable mixture of regioisomers). TLC: 70% EtOAc / heptane (Rf: 0.40). LCMS: Calculated value of C₁₉H₂₃N₅O₄: 385.42; Found value: 386.00 (M+1). ¹H NMR is complex and indicates a mixture of regioisomers.

[0280] 1-((3-(((5-chloro-2-methoxyphenyl)sulfonamide)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid tert-butyl ester and 2-((3-(((5-chloro-2-methoxyphenyl)sulfonamide)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester (8) were synthesized at 0 °C by adding a 1M solution of KOtBu in THF (5.8 mL, 5.838 mmol) to a stirred solution of compound 7 (0.75 g, 1.945 mmol) in THF (20 mL). The reaction mixture was stirred at 0 °C for 10 min, followed by the addition of 5-chloro-2-methoxybenzenesulfonyl chloride (0.70 g, 2.919 mmol). The reaction mixture was stirred at room temperature for 16 h. After completion (monitored by TLC), the mixture was quenched with water and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by combi-flash column chromatography using 50%–60% EA in heptane.To obtain title compound 8 (a mixture of regioisomers) as a grayish-white solid (0.50 g, 43.55%). TLC: 50% EtOAc / heptane (Rf: 0.5). LCMS: Calculated value of C26H28ClN5O7S: 589.14; Found value: 590.20 (M+1).

[0281] Synthesis of 5-chloro-N-(6-((5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2-methoxybenzenesulfonamide hydrochloride and 5-chloro-N-(6-((5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2-methoxybenzenesulfonamide hydrochloride (9) was carried out at 0 °C. 4M HCl (5 mL) in 1,4-dioxane was added to a stirred solution of compound 8 (0.50 g, 0.8475 mmol) in DCM (10 mL). The reaction mixture was stirred at room temperature for 4 h. (Instructions for use, page 87 / 253, 108 CN 122003411 A) After completion (monitored by TLC), the mixture was concentrated under reduced pressure. The residue was washed with Et₂O and dried under reduced pressure to give title compound 9 (a mixture of regioisomers) (0.42 g, 94.17%) as a grayish-white solid. TLC: 10% MeOH / DCM (Rf: 0.3). LCMS: Calculated value of C₂₁H₂₀ClN₅O₅S: 489.09; Found value: 490.10 (M+1).

[0282] Synthesis of 5-chloro-2-methoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthesis Example 1) and 5-chloro-2-methoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthesis Example 2) Propyrogenic acid (0.032 g, 0.455 mmol) and DIPEA (0.198 mL, 1.137 mmol) were added to a stirred solution of compound 9 (0.20 g, 0.379 mmol) in DMF (5 mL) under a N2 atmosphere at 0 °C. 50% solution of T3P in EtOAc (0.36 g, 1.139 mmol) and T3P (0.36 g, 1.139 mmol). The reaction mixture was stirred at room temperature for 2 h. After completion (monitored by TLC), the reaction mixture was quenched with water.Extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by combi-flash column chromatography using 5% MeOH in DCM to obtain a mixture of regioisomers. This mixture was further purified by chiral HPLC to obtain 5-chloro-2-methoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 1; 35 mg, 16.15%) and 5-chloro-2-methoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 2; 15 mg, 7.28%) as a grayish-white solid. TLC: 10% MeOH / DCM (Rf: 0.3) (Analytical data are shown in Table 1).

[0283] Example 3 Scheme 2: Synthesis of 2-methoxy-N-(4-methoxy-6-((5-propionyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazole-3-yl)benzenesulfonamide (Synthesis Example 3) Synthesis of 1-((4-methoxy-3-((2-methoxyphenyl)sulfonamide)benzo[d]isoxazole-6-yl)methyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid tert-butyl ester and 2-((4-methoxy-3-((2-methoxyphenyl)sulfonamide)benzo[d]isoxazole-6-yl)methyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester (10) to compound 7 (0.3 2-Methoxybenzenesulfonyl chloride (0.320 g, 1.55 mmol) and NaOtPn (0.428 g, 3.89 mmol) were added to a stirred solution in THF (5 mL). The reaction mixture was stirred at room temperature for 16 h. After completion (monitored by TLC), the mixture was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude compound was purified by combi-flash using a gradient of 70%–80% ethyl acetate.To obtain title compound 10 (a mixture of regioisomers) as a brown solid (310 mg, 71.75%). TLC: 5% MeOH / DCM (Rf: 0.6). LCMS: Calculated value of C26H29N5O7S: 555.18; Found value: 556.20 (M+1).

[0284] Synthesis of 2-methoxy-N-(4-methoxy-6-((5-(2,2,2-trifluoroacetyl)-5,6-dihydro-5l4-pyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide and 2-methoxy-N-(4-methoxy-6-((5-(2,2,2-trifluoroacetyl)-5,6-dihydro-5l4-pyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (11) TFA (0.52 mL, 6.83 mmol) was added to a stirred solution of compound 10 (a mixture of regioisomers) (0.4 g, 0.68 mmol) in DCM (4 mL) at 0 °C. The reaction was stirred at room temperature for 2 h. After completion (monitored by TLC), the reaction mixture was concentrated under reduced pressure, milled with diethyl ether, and dried under vacuum to give title compound 11 (a mixture of regioisomers) (410 mg, crude) as a brown solid. TLC: 10% MeOH / DCM (Rf: 0.5). LCMS: Calculated value of C21H21N5O5S: 455.13; Found value: 454.3 (M⁻¹).

[0285] Synthesis of 2-methoxy-N-(4-methoxy-6-((5-propionyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 3) At 0 °C, propionic acid (63 mg, 0.856 mmol), DIPEA (0.398 mL, 2.28 mmol), and a 50% solution of T3P in EtOAc (0.867 mL, 1.141 mmol) in a stirred solution of compound 11 (260 mg, 0.570 mmol) in DMF (3 mL) were added. The reaction mixture was stirred at room temperature for 2 h. After completion (monitored by TLC), the mixture was quenched with ice-cold water and extracted with EtOAc (2 x 50 mL). The organic layer was washed with brine.The product was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was ground with Et₂O₃ and purified by chiral HPLC to give 2-methoxy-N-(4-methoxy-6-((5-propionyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 3; 50 mg, 17.18%) as a grayish-white solid. Another regioisomer was not separated from the mixture in pure form. TLC: 5% MeOH / DCM (Rf: 0.4). (Analytical data are shown in Table 1) Examples 4 to 5 Scheme 3: Synthesis of 2,5-dimethoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthesis Example 4) and 2,5-dimethoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthesis Example 5) Specification 89 / 253 Page 110 CN 122003411 A Synthesized tert-butyl 1-((3-(((2,5-dimethoxyphenyl)sulfonamide)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate and tert-butyl 2-((3-(((2,5-dimethoxyphenyl)sulfonamide)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate (12) at 0 °C. KOtBu in 1M solution (5.8 mL, 5.837 mmol) in THF was added to a stirred solution of compound 7 (a mixture of regioisomers) (750 mg, 1.945 mmol) in THF (20 mL). The reaction mixture was stirred for 10 min, and then 2,5-dimethoxybenzenesulfonyl chloride (0.69 g, 2.917 mmol) was added at 0 °C. The reaction was stirred at room temperature for 16 h. After completion (monitored by TLC), the reaction mixture was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by combi-flash column chromatography using 80%–90% EA / heptane.Title compound 12 (a mixture of regioisomers) was obtained as a grayish-white solid (450 mg, 39.50%). TLC: 50% EA / heptane (Rf: 0.5). LCMS: Calculated value of C27H31N5O8S: 585.19; Found value: 586.2 (M+H).

[0286] The synthesis of N-(6-((5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2,5-dimethoxybenzenesulfonamide hydrochloride and N-(6-((5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2,5-dimethoxybenzenesulfonamide hydrochloride (13) was carried out at 0 °C. 4 M HCl (4 mL) in 1,4-dioxane was added to a stirred solution of compound 12 (450 mg, 0.768 mmol) in DCM (5 mL). The reaction mixture was stirred at room temperature for 4 h. After completion (monitored by TLC), the mixture was concentrated under vacuum. The residue was washed with diethyl ether and dried under vacuum to give title compound 13 (a mixture of regioisomers) (350 mg, 87.28%) (HCl salt) as a grayish-white solid. TLC: 10% MeOH / DCM (Rf: 0.2). LCMS: Calculated value of C22H23N5O6S: 485.14; Found value: 486.30 (M+1).

[0287] Synthesis of 2,5-dimethoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 4) and 2,5-dimethoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 5) DIPEA (0.2 mL, 1.149 mmol), propynic acid (32 mg, 0.459 mmol), and T3P were added to a stirred solution of compound 13 (200 mg, 0.383 mmol) in DMF (5 mL) at 0 °C. A 50% solution (0.87 mL, 1.149 mmol) in EtOAc was prepared. The reaction mixture was stirred at room temperature for 2 h. After completion (monitored by TLC), the mixture was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was washed with diethyl ether to give a mixture of regioisomers.The mixture was further purified by chiral HPLC to give 2,5-dimethoxy-N-(4-methoxy-6((5-propynyl-5,6-dihydropyrrolo[3,4c]pyrazole-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 4; 35 mg, 15.02%) as a grayish-white solid and 2,5-dimethoxy-N-(4-methoxy-6-((5-propynyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 5; 15 mg) as a grayish-white solid. TLC: 10% MeOH / DCM (Rf: 0.4). (Analytical data are shown in Table 1.)

[0288] Examples 6 to 7 Scheme 4: Synthesis of 2-methoxy-N-(4-methoxy-6-((4-(methylsulfonylaminomethyl)-1H-pyrazole-1-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthesis Example 6) and synthesis of ((1-((4-methoxy-3-((2-methoxyphenyl)sulfonylamino)benzo[d]isoxazol-6-yl)methyl)-1H-pyrazole-4-yl)methyl)carbamate (Synthesis Example 7) Specification 90 / 253 pages 111 CN 122003411 A Synthesis of ((1H-pyrazole-4-yl)methyl)carbamate tert-butyl ester (19) NiCl2·6H2O (5.01 g, 53.711 mmol) was added to a stirred solution of compound 18 (5 g, 53.711 mmol) in methanol (400 mL). 38.671 mmol), followed by the addition of sodium borohydride (21.00 g, 549.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h, followed by the addition of di-tert-butyl dicarbonate (24 mL, 107.422). The mixture was stirred at room temperature for 48 h. After completion (monitored by TLC), the mixture was quenched with H2O (50 mL) and evaporated under reduced pressure. The aqueous layer was extracted with EtOAc (5 x 30 mL). The combined organic layers were filtered through a diatomaceous earth mat, dried over anhydrous Na2SO4, and concentrated under vacuum.To obtain title compound 19 (2.5 g, 24%) as a blue solid. TLC: 5% MeOH / DCM (Rf: 0.30). LCMS: Calculated value of C9H15N3O2: 197.12; Found value: 198.20 (M+1).

[0289] Synthesis of ((1-(4-cyano-3-fluoro-5-methoxybenzyl)-1H-pyrazole-4-yl)methyl)tert-butyl carbamate (14) was carried out at room temperature by adding DIPEA (21.46 mL, 122.92 mmol) and compound 19 (14.54 g, 73.752 mmol) to a stirred solution of compound 5 (15 g, 61.460 mmol) in DMF (15 mL). The resulting reaction mixture was heated at 70 °C for 12 h. After completion (monitored by TLC), the mixture was cooled to room temperature, quenched with ice-cold water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude compound was purified by Combi-flash chromatography using a gradient method of 40%–70% EtOAc / heptane to give title compound 14 (12 g, 33.30%) as a colorless semi-solid. TLC: 60% EtOAc / heptane (Rf: 0.45). LCMS: Calculated value of C₁₈H₂₁FN₄O₃: 360.39; Found value: 361.00 (M+1).

[0290] Synthesis of ((1-((3-amino-4-methoxybenzo[d]isoxazol-6-yl)methyl)-1H-pyrazole-4-yl)methyl) Specification 91 / 253 pages 112 CN 122003411 A Tert-butyl carbamate (15) Acetyloxyoxime acid (0.112 g, 1.50 mmol) and K2CO3 (0.414 g, 3.0 mmol) were added to a stirred solution of compound 14 (0.2 g, 0.55 mmol) in a 6:1 mixture of DMF and H2O (7 mL) at room temperature. The reaction mixture was stirred at 60 °C for 16 h. After completion (monitored by TLC), the mixture was cooled to room temperature, quenched with ice-cold water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude compound was purified by Combi-flash chromatography using a gradient method of 40%–60% EtOAc / heptane.To obtain title compound 15 (0.1 g, 48.25%) as a brown semi-solid. TLC: 80% EtOAc / heptane (Rf: 0.40). LCMS: Calculated value of C18H23N5O4: 373.41; Found value: 374.05 (M+1).

[0291] Synthesis of tert-butyl carbamate (16) (1-((4-methoxy-3-((2-methoxyphenyl)sulfonylamino)benzo[d]isoxazol-6-yl)methyl)-1H-pyrazole-4-yl)methyl)carbamate was achieved by adding 2-methoxybenzenesulfonyl chloride (0.49 g, 2.41 mmol) to a stirred solution of compound 15 (0.45 g, 1.20 mmol) in THF (5 mL), followed by the addition of NaOtPn (0.396 g, 3.60 mmol). The resulting reaction mixture was stirred at 60 °C for 16 h. After completion (monitored by TLC), the reaction mixture was quenched with ice-cold water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude compound was purified by Combi-flash chromatography using a gradient method of 60%–80% ethyl acetate / heptane to give title compound 16 (0.130 g, 19.9%) as a brown gelatinous solid. TLC: 5% MeOH / DCM (Rf: 0.6). LCMS: Calculated value of C₂₅H₂₉N₅O₇S: 543.60; Found value: 542.1 (M⁻¹).

[0292] Synthesis of N-(6-((4-(aminomethyl)-1H-pyrazol-1-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2-methoxybenzenesulfonamide hydrochloride (17) was carried out at 0 °C by adding 4M HCl (0.5 mL, 2.39 mmol) in 1,4-dioxane to a stirred solution of compound 16 (0.13 g, 0.239 mmol) in DCM (3 mL). The reaction was stirred at room temperature for 2 h. After completion (monitored by TLC), the reaction mixture was concentrated under reduced pressure to give title compound 17 (0.1 g, 0.239 mmol) as a brown semi-solid.94.3% HCl salt). TLC: 10% MeOH / DCM (Rf: 0.5). LCMS: Calculated value of C20H22ClN5O5S: 479.10; Measured value: 442.4 (M-1).

[0293] Synthesis of 2-methoxy-N-(4-methoxy-6-((4-(methanesulfonylaminomethyl)-1H-pyrazol-1-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 6) At 0 °C, Et3N (0.11 mL, 0.812 mmol) was added to a stirred solution of compound 17 (0.13 g, 0.270 mmol) in DCM (5 mL), followed by MsCl (0.037 g, 0.324 mmol) in DCM (1 mL). The reaction mixture was stirred at 0 °C for 1 h. After completion (monitored by TLC), the mixture was quenched with water and extracted with DCM. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to give the title compound 2-methoxy-N-(4-methoxy-6-((4-(methanesulfonylaminomethyl)-1H-pyrazol-1-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 6; 30 mg, 21.24%) as a grayish-white solid. TLC: 40% EtOAc / heptane (Rf: 0.5). (Analytical data are shown in Table 1).

[0294] Synthesis of methyl carbamate ((1-((4-methoxy-3-((2-methoxyphenyl)sulfonamide)benzo[d]isoxazol-6-yl)methyl)-1H-pyrazole-4-yl)methyl)carbamate (Synthesis Example 7) At 0 °C, Et3N (0.1 mL, 0.750 mmol) was added to a solution of compound 17 (0.12 g, 0.250 mmol) in DCM (10 mL), followed by the addition of methyl chloroformate (0.028 g, 0.300 mmol) in DCM (1 mL). The reaction mixture was stirred at room temperature for 30 min. After completion (monitored by TLC), the mixture was quenched with water and extracted with DCM. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by HPLC to give the title compound ((1-((4-methoxy-3-((2-methoxyphenyl)sulfonamide)benzo[d]isoxazol-6-yl)methyl)-1H-pyrazole-4-yl)methyl)carbamate (Synthetic Example 7; 25 mg, ) as a grayish-white solid.20%). TLC: 50% EtOAc / heptane (Rf: 0.5%). (Analytical data are shown in Table 1).

[0295] Example 8 Scheme 5: Synthesis of N-((1-((3-((5-ethyl-2-methoxyphenyl)sulfonamide)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-1H-pyrazole-4-yl)methyl)acetamide (Synthesis Example 8) Synthesis of tert-butyl carbamate (20) At 0°C, a 1M solution of tBuOK in THF (1.2 mL, 1.20 mmol) was added to a stirred solution of compound 15 (0.150 g, 0.401 mmol) in THF (3 mL), followed by the addition of 5-ethyl-2-methoxybenzenesulfonyl chloride (185 mg, 0.898 mmol). The reaction mixture was stirred at 0 °C for 3 h. After completion (monitored by TLC), the mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by a gradient method of 40%–60% EtOAc / heptane using combi-flash column chromatography to give title compound 20 (130 mg, 56.76%) as a grayish-white solid. TLC: 80% EtOAc / heptane (Rf: 0.35). LCMS: Calculated value of C₂₇H₃₃N₅O₇S: 571.21; Found value: 572.03 (M+1).

[0296] Synthesis of N-(6-((4-(aminomethyl)-1H-pyrazol-1-yl)methyl)-4-methoxybenzo[d]isooxazol-3-yl)-5-ethyl-2-methoxybenzenesulfonamide hydrochloride (21) was carried out at 0 °C. 4 M HCl (2 mL) in 1,4-dioxane was added to a stirred solution of compound 20 (130 mg, 0.227 mmol) in DCM (2 mL). The reaction mixture was stirred at room temperature for 2 h. After completion (monitored by TLC), the mixture was evaporated under reduced pressure. The crude product was ground together with DCM / heptane to give title compound 21 (100 mg, 0.227 mmol) as a grayish-white solid.Salt). TLC: 5% MeOH / DCM (Rf: 0.3). LCMS: Calculated value of C22H25N5O5S: 471.16; Found value: 472.30. Synthesis of N-((1-((3-((5-ethyl-2-methoxyphenyl)sulfonylamino)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-1H-pyrazole-4-yl)methyl)acetamide (Synthetic Example 8) Triethylamine (0.082 mL, 0.590 mmol) was added to a stirred solution of compound 21 (100 mg, 0.196 mmol) in DCM (3 mL) at 0 °C. The reaction mixture was stirred for 10 min, and then Ac2O (0.022 mL, 0.235 mmol) in DCM (1 mL) was added at 0 °C. The reaction mixture was stirred at room temperature for 1 h. After completion (monitored by TLC), the mixture was quenched with water and extracted with DCM. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC to give N-((1-((3-) acetamide ((5-ethyl-2-methoxyphenyl)sulfonamide)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-1H-pyrazole-4-yl)methyl)acetamide (Synthetic Example 8; 45 mg, 44.55%) as a grayish-white solid. TLC: 10% MeOH / DCM (Rf: 0.5). (Analytical data are shown in Table 1.)

[0297] Example 9 Scheme 6: Synthesis of 5-ethyl-2-methoxy-N-(4-methoxy-6-((6-propynyl-5,6,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthesis Example 9) Synthesis of 1-(4-cyano-3-fluoro-5-methoxybenzyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-6(1H)-carboxylate tert-butyl ester and 2-(4-cyano-3-fluoro-5-methoxybenzyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-6(2H)-carboxylate tert-butyl ester (22) To compound 5 (0.75 g, 3.073 mmol) DIPEA (1.6 mL, 9.219 mmol) was added to a stirred solution in DMF (7 mL), followed by tert-butyl 4,5,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-6(1H)-carboxylate (0.729 g, 3.073 mmol). The reaction mixture was stirred at 60 °C for 16 h. After completion (monitored by TLC),The mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the title compound 22 (1.2 g, crude) as a brown liquid. TLC: 40% EtOAc / heptane (Rf: 0.4). LCMS: Calculated value of C21H25FN4O3: 400.19; Measured value: 400.30. Synthesis of tert-butyl 1-((3-amino-4-methoxybenzo[d]isoxazol-6-yl)methyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-6(1H)-carboxylate and tert-butyl 2-((3-amino-4-methoxybenzo[d]isoxazol-6-yl)methyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-6(2H)-carboxylate (23). K2CO3 (2.48 g, 17.979 mmol) was added to compound 22 (1.2 g, 2.996 mmol) in a mixture of DMF: H2O (48 mL, 6:1 ratio). And N-hydroxyacetamide (0.674 g, 8.988 mmol). The reaction mixture was stirred at 70 °C for 16 h. After completion (monitored by TLC), the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give title compound 23 (750 mg, 60.53%) as a yellow solid. TLC: 40% EtOAc / heptane (Rf: 0.4). LCMS: Calculated value of C₂₁H₂₇N₅O₄: 413.21; Found value: 414.5 (M+1).

[0298] Synthesis of tert-butyl 1-((3-(((5-ethyl-2-methoxyphenyl)sulfonylamino)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-6(1H)-carboxylate and tert-butyl 2-((3-((5-ethyl-2-methoxyphenyl)sulfonylamino)-4-methoxybenzo[d]isoxazol-6-yl)methyl)-4,5,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-6(2H)-carboxylate (24) was carried out at 0°C. NaOtBu (0.87 g, 9.069 g) was added to a stirred solution of compound 23 (750 mg, 1.813 mmol) in THF (8 mL). mmol), followed by the addition of 5-ethyl-2-methoxybenzenesulfonyl chloride (0.510 g, CN 122003411 A, page 94 / 253, instruction manual 2.175 mmol). The reaction mixture was stirred at room temperature for 16 h. After completion (monitored by TLC),The reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the title compound 24 (1.1 g, 99.18%) as a brown, gelatinous oil. This crude product was used for the next step without further purification. TLC: 40% EtOAc / heptane (Rf: 0.4). LCMS: Calculated value of C₃₀H₃₇N₅O₇S: 611.24; Found value: 612.5 (M+1).

[0299] 5-Ethyl-2-methoxy-N-(4-methoxy-6-((5,6,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide hydrochloride and 5-Ethyl-2-methoxy-N-(4-methoxy-6-((5,6,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-2(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide hydrochloride (25) were synthesized at 0 °C. 4M HCl (5 mL) in 1,4-dioxane was added to a solution of compound 24 (1.0 g, 1.63 mmol) in DCM (10 mL), and the reaction mixture was stirred at room temperature for 4 h. After completion (monitored by TLC), the mixture was concentrated under reduced pressure. The residue was washed three times with diethyl ether and dried under vacuum to give title compound 25 (750 mg, HCl salt) as a grayish-white solid. The crude product was used in the next reaction. It was ready for use without further purification. TLC: 40% EtOAc / heptane (Rf: 0.4). LCMS: Calculated value of C25H29N5O5S: 511.19; Measured value: 512.30. Synthesis of 5-ethyl-2-methoxy-N-(4-methoxy-6-((6-propynyl-5,6,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 9) At 0°C, DIPEA (0.716 mL, 4.104 mmol) and a 50% solution of T3P in EtOAc (5.22 mL, 8.208 mmol) were added to a stirred solution of compound 25 (0.750 g, 1.368 mmol) and propynyl-2-alkynic acid (0.143 g, 2.052 mmol) in DMF (7.5 mL) with stirring. (mmol). The reaction mixture was stirred at room temperature for 2 h. After completion (monitored by TLC), the mixture was quenched with water and extracted with DCM. The organic layer was dried over anhydrous Na2SO4.The product was concentrated under reduced pressure. The crude product was purified by combi-flash chromatography (5% MeOH in DCM) followed by preparative HPLC to obtain the desired compound as a mixture of regioisomers. The desired regioisomer (Synthetic Example 9) was obtained by subjecting the mixture to preparative SFC to give 5-ethyl-2-methoxy-N-(4-methoxy-6-((6-propynyl-5,6,7,8-tetrahydropyrazolo[3,4-d]azacycloheptatrien-1(4H)-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 9; 55 mg, 7.13%) as a grayish-white solid. Other regioisomers were not separated. TLC: 10% MeOH / DCM (Rf: 0.5). (Analytical data are shown in Table 1.)

[0300] Example 10 Scheme 7: Synthesis of 2,4-dimethoxy-N-(4-methoxy-6-((4-(methylsulfonylaminomethyl)-1H-pyrazole-1-yl)methyl)benzo[d]isoxazole-3-yl)benzenesulfonamide (Synthesis Example 10) Synthesis of ((1-((3-((2,4-dimethoxyphenyl)sulfonylamino)-4-methoxybenzo[d]isoxazole-6-yl) tert-butyl carbamate (26) At 0°C, 1M solution (4 mL, 4.017 mmol) of KOtBu solution in THF was added to a stirred solution of compound 15 (500 mg, 1.339 mmol) in THF (15 mL). The reaction mixture was stirred at 0 °C for 10 min, followed by the addition of 0.475 g (2.008 mmol) of 2,4-dimethoxybenzenesulfonyl chloride in 1 mL of THF. The reaction was stirred at room temperature for 16 h. After completion (monitored by TLC), the mixture was quenched with 1 N HCl and extracted with ethyl acetate. The organic layer was dried over anhydrous Na₂SO₄.The sample was concentrated under reduced pressure. The crude product was purified by combi-flash chromatography (neutral alumina) using a 30%–50% EA / heptane gradient to give the title compound 26 (140 mg, 18.22%) as a pale yellow solid. TLC: 10% MeOH / DCM (Rf: 0.6). LCMS: Calculated value of C26H31N5O8S: 573.62; Found value: 574.06 (M+1).

[0301] Synthesis of N-(6-((4-(aminomethyl)-1H-pyrazol-1-yl)methyl)-4-methoxybenzo[d]isoxazol-3-yl)-2,4-dimethoxybenzenesulfonamide hydrochloride (27): 4M HCl (2 mL) in 1,4-dioxane was added to a stirred solution of compound 26 (140 mg, 0.274 mmol) in DCM (3 mL). The reaction mixture was stirred at room temperature for 4 h. After completion (monitored by TLC), the mixture was concentrated under reduced pressure. The residue was washed with diethyl ether to give title compound 27 (110 mg, 74.24%) (HCl salt) as a grayish-white solid. TLC: 10% MeOH / DCM (Rf: 0.6). LCMS: Calculated value of C21H23N5O6S: 473.14; Found value: 474.20. Synthesis of 2,4-dimethoxy-N-(4-methoxy-6-((4-(methanesulfonylaminomethyl)-1H-pyrazol-1-yl)methyl)benzo[d]isoxazol-3-yl)benzenesulfonamide (Synthetic Example 10) At 0 °C, triethylamine (0.09 mL, 0.647 mmol) was added to a stirred solution of compound 27 (110 mg, 0.2157 mmol) in DCM (3 mL), followed by methanesulfonyl chloride (0.029 g, 0.2588 mmol) in DCM (1 mL). The reaction mixture was stirred at room temperature for 15 min. After completion (monitored by TLC)...

Claims

1. A compound of formula I: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X represents O and S(O). x Or CH2, where x is 0 to 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 20 R 21 .

2. A compound of formula I: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Choose from (i) or (ii): (i) R 1 It is H, alkyl, haloalkyl, or halogen; and R 2 It is an alkyl, cycloalkyl, or haloalkyl group, or (ii) R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 For CR 16 ; Z 5 For CR 5 ; Z 6 For N or CH; R 5 and R 16 Together they form alkylene or heteroalkylene; X represents O and S(O). x Or CH2, where x is 0 to 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 9 R 10 .

3. A compound of formula I: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Choose from (i) or (ii): (i) R 1 It is H, alkyl, haloalkyl, or halogen; and R 2 It is an alkyl, cycloalkyl, or haloalkyl group, or (ii) R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X is either O or S(O). x , where x is between 0 and 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 9 R 10 .

4. A compound of formula I: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 It can be H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; R 2 and R 4 Together they form heteroalkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X represents O and S(O). x Or CH2, where x is 0 to 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 9 R 10 .

5. A compound of formula I: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 It is H, alkyl, haloalkyl, or halogen; R 2 It is an alkyl, cycloalkyl, or haloalkyl group; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X is CR 22 R 23 , where R 22 and R 23 Each is independently H or alkyl; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 ;and R 17 It is an alkoxy, alkenyloxy, alkynyloxy, or -O-(CH2)2-R 19 ;where R 19 For -OR 9 or -NR 9 R 10 .

6. The compound according to any one of claims 1 to 5, having formula Ia: Or its pharmaceutically acceptable derivatives.

7. The compound according to any one of claims 1 to 6, wherein: R 1 For H; R 2 It is an alkyl, cycloalkyl, or haloalkyl group; R 8 For H, CN, OH, aryl, heteroaryl, NR 9 R 10 or C(O)R 11 ; R 9 and R 10 Each is independently H or C(O)R 13 ;where R 13 It is an alkyl or alkoxy group; R 11 It is an alkyl or alkoxy group; X is CH2; and R 17 It is an alkoxy group.

8. The compound according to any one of claims 1 to 7, wherein: R 1 For H; R 2 It is an alkyl or haloalkyl group; R 8 For H, CN, OH, aryl, NR 9 R 10 or C(O)R 11 ; R 9 and R 10 Each is independently H or C(O)R 13 ;where R 13 It is an alkyl group; R 11 It is an alkoxy group; X is CH2; and R 17 It is an alkoxy group.

9. A compound of formula II: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X represents O and S(O). x Or CH2, where x is 0 to 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 20 R 21 .

10. A compound of formula II: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Choose from (i) or (ii); (i) R 1 It is an alkyl, cycloalkyl, or haloalkyl group; and R 2 It is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen, or (ii) R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 For CR 16 ; Z 5 For CR 5 ; Z 6 For N or CH; R 5 and R 16 Together they form alkylene or heteroalkylene; X represents O and S(O). x Or CH2, where x is 0 to 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 9 R 10 .

11. A compound of formula II: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Choose from (i) or (ii): (i) R 1 It is an alkyl, cycloalkyl, or haloalkyl group, and R 2 It is H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen, or (ii) R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X is either O or S(O). x , where x is between 0 and 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 9 R 10 .

12. A compound of formula II: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 It is an alkyl, cycloalkyl, or haloalkyl group; R 2 It can be H, alkyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, or halogen; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X is CR 22 R 23 , where R 22 and R 23 Each is independently H or alkyl; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 ;and R 17 It is an alkoxy, alkenyloxy, alkynyloxy, or -O-(CH2)2-R 19 ;where R 19 For -OR 9 or -NR 9 R 10 .

13. The compound according to any one of claims 9 to 12, wherein the compound has formula IIa: Or its pharmaceutically acceptable derivatives.

14. The compound according to any one of claims 9 to 13, wherein: R 1 It is an alkyl, cycloalkyl, or haloalkyl group; R 2 For H; R 8 For H, CN, OH, aryl, heteroaryl, NR 9 R 10 or C(O)R 11 ; R 9 and R 10 Each is independently H or C(O)R 13 ;where R 13 It is an alkyl or alkoxy group; R 11 It is an alkyl or alkoxy group; X is CH2; and R 17 It is an alkoxy group.

15. The compound according to any one of claims 9 to 13, wherein: R 1 It is an alkyl or haloalkyl group; R 2 For H; R 8 For H, CN, OH, aryl, NR 9 R 10 or C(O)R 11 ; R 9 and R 10 Each is independently H or C(O)R 13 ;where R 13 It is an alkyl group; R 11 It is an alkoxy group; X is CH2; and R 17 It is an alkoxy group.

16. A compound of formula III: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X represents O and S(O). x Or CH2, where x is 0 to 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 20 R 21 .

17. A compound of formula III: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Choose from (i) or (ii): (i) R 1 and R 2 Each is independently an alkyl, cycloalkyl, or haloalkyl group, or (ii) R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 For CR 16 ; Z 5 For CR 5 ; Z 6 For N or CH; R 5 and R 16 Together they form alkylene or heteroalkylene; X represents O and S(O). x Or CH2, where x is 0 to 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 9 R 10 .

18. A compound of formula III: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Choose from (i) or (ii): (i) R 1 and R 2 Each is independently an alkyl, cycloalkyl, or haloalkyl group, or (ii) R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 Z 5 and Z 6 Choose from (i), (ii), (iii), or (iv): (i) Z 4 For N, Z 5 For CR 5 And Z 6 For CH, (ii) Z 4 For CR 16 Z 5 Let N be the number of elements, and Z be the number of elements. 6 For CH, (iii) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For N, or (iv) Z 4 For CR 16 Z 5 For CR 5 And Z 6 For CH; R 5 and R 16 Choose from (i) or (ii): (i) R 5 and R 16 Each is independently H, cyano, halogen, alkoxy, amino, alkylamino, dialkylamino, alkyl, alkenyl, ynyl, or haloalkyl, or (ii) R 5 and R 16 Together they form alkylene or heteroalkylene; X is either O or S(O). x , where x is between 0 and 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 -S(O)R 18 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 9 R 10 .

19. The compound according to any one of claims 16 to 18, wherein the compound has formula IIIa: 。 20. A compound of formula IIIa: or pharmaceutically acceptable derivatives thereof, wherein: a is between 0 and 2; R 1 and R 2 Choose from (i) or (ii): (i) R 1 and R 2 Each is independently an alkyl, cycloalkyl, or haloalkyl group, or (ii) R 1 and R 2 Together they form alkylene groups; R 3 For -O-(CH2) b -R 8 ; b ranges from 1 to 4; R 8 The radicals are H, CN, OH, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, and NR. 9 R 10 C(O)R 11 C(=NH)(R) 12 ) or C(=NOR 9 (R) 12 ); R 9 and R 10 Each is independently H, alkyl, or C(O)R 13 ;where R 13 Alkyl, alkoxy or NR 14 R 15 ; R 11 Hydroxyl, alkyl, alkoxy or NR 14 R 15 ; R 12 alkyl or NR 14 R 15 ; R 14 and R 15 Each can be independently H, OH, alkoxy, or alkyl, or together with the nitrogen atom to which they are attached, form a heterocyclic group; R 4 It is H or alkoxy; Z 1 Z 2 and Z 3 Choose from (i), (ii), or (iii): (i) Z 1 For N, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N. (ii) Z 1 It is NH or O, and Z 2 and Z 3 For C, or (iii) Z 1 For CH, Z 2 and Z 3 One of them is C, and Z 2 and Z 3 The other one is N; Z 4 For N or CR 16 , where R 16 It can be H, alkyl, haloalkyl, alkoxy, halogen, alkenyl or alkynyl; R 5 It can be H, alkyl, haloalkyl, alkoxy, halogen, alkenyl or alkynyl; X represents O and S(O). x Or CH2, where x is 0 to 2; Het and R 6 Choose from (i) or (ii): (i) Het is a 5- or 6-membered heteroaryl group, and R 6 It is H, alkyl or haloalkyl, or (ii) Het is a 5- or 6-membered heteroaryl group, R 6 For –(CH2) 1-2 – and R 6 Together with the atoms they are attached to, Het forms 5,5-, 5,6-, 5,7-, 6,5-, 6,6- or 6,7- bicyclic ring systems; R 7 -C(O)R 17 or -SO2R 18 ; R 17 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, methylaminomethylalkenyl, dimethylaminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, methylaminomethylalkynyl, dimethylaminomethylalkynyl, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, -NH-(CH2)2-R 19 -O-(CH2)2-R 19 or -NR 20 R 21 ;where R 19 For -OR 9 or -NR 9 R 10 And R 20 and R 21 Each is independently H, alkyl, cycloalkyl, or haloalkyl; and R 18 Alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, cyanoalkenyl, hydroxymethylalkenyl, alkoxymethylalkenyl, aminomethylalkenyl, alkynyl, haloalkynyl, cyanoalkynyl, hydroxymethylalkynyl, alkoxymethylalkynyl, aminomethylalkynyl, or -NR 9 R 10 .

21. The compound according to any one of claims 16 to 20, wherein: R 1 and R 2 Choose from (i) or (ii): (i) R 1 and R 2 Each is an alkyl group, or (ii) R 1 and R 2 Together they form alkylene groups; R 8 For H, CN, OH, aryl, heteroaryl, NR 9 R 10 or C(O)R 11 ; R 9 and R 10 Each is independently H or C(O)R 13 ;where R 13 It is an alkyl or alkoxy group; R 11 It is an alkyl or alkoxy group; R 5 and R 16 Together they form alkylene groups; X is O or CH2; R 17 It is an alkyl, haloalkyl, alkoxy, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl, or hydroxymethylynyl; and R 18 It can be alkyl, haloalkyl, alkoxyalkyl, aminoalkyl, alkenyl, haloalkenyl, ynyl or hydroxymethylynyl.

22. The compound according to any one of claims 1 to 4, 6, 9 to 11, 13 and 16 to 21, wherein X is O.

23. The compound according to any one of claims 1, 2, 4 to 10 and 11 to 21, wherein X is CH2.

24. The compound according to any one of claims 1 to 23, wherein a is 0 or 1.

25. The compound according to any one of claims 1 to 8, wherein R 2 It is an alkyl group.

26. The compound according to any one of claims 1 to 8, wherein R 2 It is a haloalkyl group.

27. The compound according to any one of claims 1 to 8, wherein R 2 It is difluoromethyl.

28. The compound according to any one of claims 9 to 15, wherein R 1 It is an alkyl group.

29. The compound according to any one of claims 9 to 15, wherein R 1 It is a haloalkyl group.

30. The compound according to any one of claims 9 to 15, wherein R 1 It is difluoromethyl.

31. The compound according to any one of claims 1 to 6, wherein R 1 For H.

32. The compound according to any one of claims 9 to 15, wherein R 2 For H.

33. The compound according to any one of claims 16 to 21, wherein R 1 and R 2 Together they form C14 groups optionally substituted with one or more halogens or methyl groups. 1-4 Alkylene.

34. The compound according to any one of claims 1 to 33, wherein b is 1 or 2.

35. The compound according to any one of claims 1 to 6, 9 to 13, and 16 to 21, wherein R 8 It can be H, phenyl, 4-fluorophenyl, morpholino, COOH, COOMe, C(=NH)NHOH, tetrazolyl, oxadiazolyl, triazolyl, pyridyl, imidazolyl, oxazolidinyl, NHC(O)OMe, cyano, hydroxyl, amino, or acetamido.

36. The compound according to any one of claims 1 to 35, wherein R 8 It is hydrogen.

37. The compound according to any one of claims 1 to 36, wherein R 4 For H.

38. The compound according to any one of claims 1 to 37, wherein R 4 It is a methoxy group.

39. The compound according to any one of claims 1 to 38, wherein Z 1 It is NH or O, and Z 2 and Z 3 The answer is C.

40. The compound according to any one of claims 1 to 39, wherein Z 1 It is O, and Z 2 and Z 3 The answer is C.

41. The compound according to any one of claims 1 to 40, wherein Z 4 Let N be the number of elements in the array.

42. The compound according to any one of claims 1 to 40, wherein Z 4 For CR 16 .

43. The compound according to any one of claims 1 to 42, wherein R 5 It is H, cyano, alkoxy, or alkyl, and R 16 It can be H, alkyl, alkoxy, halogen, or alkynyl.

44. The compound according to any one of claims 1 to 43, wherein R 5 It is H, cyano, methoxy, or methyl, and R 16 It can be H, methyl, ethyl, isopropyl, tert-butyl, methoxy, chlorine, fluorine, ethynyl, or propynyl.

45. The compound according to any one of claims 1 to 44, wherein Het is a 5- or 6-membered heteroaryl group, and R 6 It is H or alkyl.

46. ​​The compound according to any one of claims 1 to 45, wherein Het is a 5-membered heteroaryl group, and R 6 It can be H or methyl.

47. The compound according to any one of claims 1 to 46, wherein Het is pyrazolyl, oxazolyl, thiazolyl, or pyridinyl, and R 6 It can be H or methyl.

48. The compound according to any one of claims 1 to 47, wherein Het is a pyrazolyl group, and R 6 It can be H or methyl.

49. The compound according to any one of claims 1 to 48, wherein R 7 -C(O)R 17 .

50. The compound according to any one of claims 1 to 48, wherein R 7 -S(O)R 18 .

51. The compound according to any one of claims 1 to 48, wherein R 7 -SO2R 18 .

52. The compound according to any one of claims 1 to 6, 9 to 13, and 16 to 21, wherein R 17 Alkyl, alkoxy, alkenyl, haloalkenyl, alkynyl, NR 20 R 21 Or hydroxyalkynyl group.

53. The compound according to any one of claims 1 to 6, 9 to 13, and 16 to 21, wherein R 17 It can be methyl, methoxy, NHMe, vinyl, 1-fluoro-1-vinyl, ethynyl or 1-propynyl-1-yl.

54. The compound according to any one of claims 1 to 53, wherein R 18 It is methyl or tert-butyl.

55. The compound according to any one of claims 1 to 54, wherein the compound is any of the compounds disclosed herein.

56. A pharmaceutical composition comprising: a compound according to any one of claims 1 to 55; and a pharmaceutically acceptable carrier.

57. A method of treating a subject suffering from cancer, the method comprising administering to the subject a compound according to any one of claims 1 to 55 or a pharmaceutical composition according to claim 56.

58. A method of treating a subject with myc-driven cancer, the method comprising administering to the subject a compound according to any one of claims 1 to 55 or a pharmaceutical composition according to claim 56.